UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act file number: 811-21583
Clough Global Dividend and Income Fund
(exact name of registrant as specified in charter)
1290 Broadway, Suite 1000, Denver, Colorado 80203
(Address of principal executive offices) (Zip code)
Sareena Khwaja-Dixon, Secretary
Clough Global Dividend and Income Fund
1290 Broadway, Suite 1000
Denver, Colorado 80203
(Name and address of agent for service)
Registrant’s telephone number, including area code: 877-256-8445
Date of fiscal year end: October 31
Date of reporting period: November 1, 2019 – October 31, 2020
Item 1. Reports to Stockholders.
Section 19(b) Disclosure |
October 31, 2020 (Unaudited)
Clough Global Dividend and Income Fund, Clough Global Equity Fund, and Clough Global Opportunities Fund (each a “Fund” and collectively, the “Funds”), acting pursuant to a Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Fund’s Board of Trustees (the “Board”), have adopted a plan, consistent with each Fund’s investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the “Plan”). In accordance with the Plan, through December 2019, each Fund paid monthly distributions in an annualized amount of not less than 10% of the respective Fund’s average monthly net asset value (“NAV”). Effective January 1, 2020, the Funds’ managed distribution policy was revised to set the monthly distribution rate at an amount equal to one twelfth of 10% of each Fund’s adjusted year-ending NAV, which is the average of the NAVs as of the last five business days of the prior calendar year. Until July 2021, each Fund will pay monthly distributions in an amount not less than the average distribution rate of a peer group of closed-end funds selected by the Board.
Under the Plan, each Fund will distribute all available investment income to its shareholders, consistent with each Fund’s primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient investment income is not available on a monthly basis, each Fund will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution.
Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board, except for extraordinary distributions and potential distribution rate increases to enable each Fund to comply with the distribution requirements imposed by the Code.
Shareholders should not draw any conclusions about each Fund’s investment performance from the amount of these distributions or from the terms of the Plan. Each Fund’s total return performance on net asset value is presented in its financial highlights table.
Until July 2021, each Board may amend, suspend or terminate each Fund’s Plan without prior notice if the Board determines in good faith that continuation would constitute a breach of fiduciary duty or would violate the Investment Company Act of 1940.
The suspension or termination of the Plan could have the effect of creating a trading discount (if a Fund’s stock is trading at or above net asset value) or widening an existing trading discount. Each Fund is subject to risks that could have an adverse impact on its ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, increased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to the Notes to Financial Statements in the Annual Report to Shareholders for a more complete description of its risks.
Please refer to Additional Information for a cumulative summary of the Section 19(a) notices for each Fund’s current fiscal period. Section 19(a) notices for each Fund, as applicable, are available on the Clough Global Closed-End Funds website www.cloughglobal.com.
Clough Global Funds | Table of Contents |
Shareholder Letter & Portfolio Allocation | |
Clough Global Dividend and Income Fund | 2 |
Clough Global Equity Fund | 7 |
Clough Global Opportunities Fund | 12 |
Statement of Investments | |
Clough Global Dividend and Income Fund | 17 |
Clough Global Equity Fund | 22 |
Clough Global Opportunities Fund | 26 |
Statements of Assets and Liabilities | 31 |
Statements of Operations | 32 |
Statements of Changes in Net Assets | 33 |
Statements of Cash Flows | 36 |
Financial Highlights | |
Clough Global Dividend and Income Fund | 38 |
Clough Global Equity Fund | 39 |
Clough Global Opportunities Fund | 40 |
Notes to Financial Statements | 41 |
Report of Independent Registered Public Accounting Firm | 60 |
Dividend Reinvestment Plan | 61 |
Additional Information | |
Fund Proxy Voting Policies & Procedures | 62 |
Portfolio Holdings | 62 |
Notice | 62 |
Shareholder Meeting | 62 |
Section 19(A) Notices | 63 |
Tax Designations | 63 |
Trustees & Officers | 64 |
Summary of Updated Information Regarding Clough Global Dividend and Income Fund | 68 |
Summary of Updated Information Regarding Clough Global Equity Fund | 86 |
Summary of Updated Information Regarding Clough Global Opportunities Fund | 103 |
Privacy Policy | 122 |
Beginning on January 1, 2021, as permitted by regulations adopted by the U.S. Securities and Exchange Commission, paper copies of the Funds’ annual and semi-annual shareholder reports will no longer be sent by mail, unless you specifically request paper copies of the reports. Instead, the reports will be made available on the Funds’ website at www.cloughglobal.com, and you will be notified by mail each time a report is posted and provided with a website link to access the report.
Beginning on January 1, 2019, you may, notwithstanding the availability of shareholder reports online, elect to receive all future shareholder reports in paper free of charge. If you invest through a financial intermediary, you can contact your financial intermediary to request that you continue to receive paper copies of your shareholder reports. If you invest directly with a Fund, you can call 1-866-226-8017, from 8am to 5pm CT, to let the Fund know you wish to continue receiving paper copies of your shareholder reports.
If you already elected to receive shareholder reports electronically, you will not be affected by this change and you need not take any action. You may elect to receive shareholder reports and other communications from a Fund electronically anytime by contacting your financial intermediary (such as a broker-dealer or bank) or, if you are a direct investor, by calling 1-866-226-8017.
Clough Global Dividend and Income Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
For the fiscal year ending October 31, 2020, the Clough Global Dividend and Income Fund (“GLV” or the “Fund”) was down -4.75% on net asset value (“NAV”) and down -9.59% on market price. The Fund’s benchmark, 50% MSCI World Index/50% Bloomberg Barclays U.S. Aggregate Bond Index, was up 6.21% for the same period.
TOP FIVE CONTRIBUTORS AND DETRACTORS FOR THE YEAR
The Fund’s investment in Eurodollar futures as a hedge against a slowing global economy due to the emerging pandemic proved to be the largest contributor to performance for the year. Eurodollar futures, which are a proxy for future central bank policy, allowed the Fund to maintain its long equity book in the turbulent months of February and March while participating in the recovery rally that started in April. The Fund continues to hold this position as an intended hedge against any additional slow down in economic activity from the spread of COVID-19.
PennyMac Financial Services Inc., a market dominant originator and servicer of residential and commercial mortgages, was a top contributor that benefited from increased refinance and new buyer activity as mortgage rates reached all time lows. Apple Inc. and Microsoft Corp. made significant gains from the COVID-19 driven shift to a stay at home economy. Finally, MediaTek Inc., a key beneficiary from the development of 5G technology, was also top performer for the fiscal year.
Financial stocks were the top detractors for the year. Citigroup Inc., along with mortgage real estate investment trust (“REIT”) PennyMac Mortgage Investment Trust and commercial REIT Ladder Capital Corp., all declined as the markets priced in meaningful losses to the companies’ portfolios due to the sudden collapse in economy from COVID-19 related shutdowns. Finally, as the markets recovered in the spring, hedge positions in a S&P 500 Index exchange traded fund (“ETF”) and options on the S&P 500 Index were also top detractors from performance.
ON THE MARKETS: LIQUIDITY SUPPORT FOR EQUITIES IS POSITIVE
We are not political experts, but it appears equities have embraced a Biden presidency along with the possibility of a small Republican majority in the Senate and we can understand why. It is widely expected that there will be better coordination between a Biden administration and the Federal Reserve (the “Fed”) in combining monetary and fiscal policies. A Biden administration is expected to push for additional stimulus packages, and we assume will appoint dovish Federal Reserve governors.
The coronavirus was more of an exogenous shock to the market than would be a natural recession. There was no credit crisis or banking collapse, nor was there a profit hit from an excessive capacity build which destroys profitability in a key economic sector, like technology in 2000 or housing in 2008. The threat of more infections would likely prolong the policies of monetary ease.
The Fed is currently pumping liquidity into a growing economy and if it lives up to its promises of sustaining zero nominal interest rates into 2022 or 2023, the likelihood of higher returns on investment in the economy in 2021 and beyond looks pretty good.
In the meantime, investors are positioned defensively, holding $4.5 trillion in money market funds and another $15.7 trillion in short-term deposits. The amount of money sitting at the 90-day rate is close to the nominal gross domestic product (“GDP”). The Fed would like to see that money invested in the economy and is making holding that cash very costly.
The Fed is the most critical factor to the markets. Financial conditions are incredibly favorable, earnings expectations are rising, and the Fed continues to add reserves to the banking system. All of that is positive for equities.
Finally, businesses continue to generate large amounts of cash flow according to Bloomberg. Because business investment has been well below that spent in previous business expansions, businesses did not over invest, and excess capacity was never built, so pricing and profitability have held up. With the Pfizer vaccine likely to begin distribution over the next few months, we believe 2021 could be a very strong year for equities.
TECHNOLOGY
Looking ahead through the 2020s, we believe that the global buildout of 5G telecommunications networks will be a significant investment opportunity. All of the imaginative projects of the 2020s such as autonomous driving, machine learning and the “Internet of Things” require 5G technology. The 5G rollout accelerated with Apple’s announcement of a suite of its 5G equipped iPhones, which promise faster download and upload speeds, higher latency, and quality video gaming and streaming as enticements to buy the phones. Consumer spending is being diverted from travel and leisure to consumer electronics and evidence is mounting that affluent consumers will buy high-end phones. So far, 5G is widely available only in the Asia Pacific region, but where it is available selling prices are 15-20% higher than those of 4G equipped phones. Even in areas where 5G is not available, new phones are selling at a 7% premium to earlier generations.
2 | www.cloughglobal.com |
Clough Global Dividend and Income Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
Hundreds of billions of dollars will be spent building out 5G, and competition will be intense, particularly among service providers and companies which build the commodity portions of the infrastructure. To be competitive, service providers will be forced to overbuild their networks ahead of demand and to discount their products to fill capacity. Handset manufacturers without the strong applications businesses which lock in customers, unlike Apple which does, will also have to price aggressively to sell their products. A move to a new standard could add $50-100 per phone to the materials bill, especially for radio frequency (“RF”) chips, processing power and added memory. High-end phone modems must be able to work with any phone in any market and that is expensive. For example, the cost of the modem alone in 5G can increase by more than 50%. So, it is necessary to answer the question: who will capture the profits?
Higher materials costs mean more 5G dollars will go to the supply chain companies which solve the bottlenecks, the parts of the networks where proprietary technology breakthroughs are critical to making 5G work. The semiconductor companies with the technologies that solve those problems will not only capture a larger percentage of the phone’s value, but also should lock in the highest profit margins.
A major barrier to entry in semiconductor manufacturing is a sharp rise in the capital intensity of component manufacturing. Taiwan Semiconductor Manufacturing Co Ltd. (“TSMC”), a current holding in the Fund, is expected to invest $130 billion through 2030 for high-end foundries for processor chips, an area where the company is already dominant. As capital intensity in the semiconductor industry rises, TSMC gains scale from share gains, and assumes pricing power and market share. Its foundry capacity is ten times that of Samsung’s and Chinese foundries barely compete in the space. TSMC has leading edge semiconductor design and production to the point that the company has already captured the leadership in processors from Intel Corp., and it already produces 20% of Intel’s sales. TSMC, with the industry’s first five nanometer A14 bionic chip, will provide the processors for all of Apple’s models offering speeds of up to 50% faster. Yet the stock has underperformed, and we believe it is relatively inexpensive.
We have particularly focused on companies that make up the Apple supply chain. For example, Skyworks Solutions Inc. is a manufacturer of RF chips whose products might be expected to capture a larger percentage of the iPhone’s revenues. Prior to 4G, radio frequency content per phone was about $10 for each smartphone. That rose to $20-30 per phone for 4G and will likely reach $35-40 for each 5G phone. Approximately 50% of the company’s revenues are from Apple.
Samsung Electronics Co Ltd. is also a current holding in the Fund. In memory and non-memory chips, the company has unexcelled research and development (“R&D”) and only trails Huawei Technologies Co Ltd. in announced patents. Now the company is making inroads into the manufacturing of 5G infrastructure, including high-end image sensors and foundry capacity. Its share of the telecom market, once a modest 4% or so for 4G, has risen to 10-15% for 5G. Not only is the company picking up on Huawei’s decline, but it has a secure supply chain located in Vietnam and South Korea. It has little China exposure and has far stronger R&D than either LM Ericsson or Nokia Oyj. The company successfully picked up a key Verizon 5G contract to supply 5G radio access equipment through 2025. Yet the stock sells at roughly book value, 11x 2021 earnings per share, offers a 3.5% yield, and its roughly $300 billion market capitalization includes $94 billion in cash.
HEALTHCARE
COVID-19 has created significant business opportunities for innovative healthcare companies, but a successful vaccine may not be the only positive advancement. In our view, telemedicine and pharmaceutical testing may actually present some of the best long-term profit opportunities. COVID-19 accelerated the shift to telemedicine from in-office visits and the convertible bond of Teladoc Health Inc., the largest company in the telemedicine space, is a current holding in the Fund. Meanwhile, testing is becoming one of the fastest growing sectors in healthcare. We think the market underappreciates the critical role testing companies will continue to play, even with a vaccine approval. The Fund’s testing-related holdings include Thermo Fisher Scientific Inc. and Quest Diagnostics Inc. It should also be noted that Thermo Fisher is one of the leading providers of the refrigeration services that will be required to store COVID-19 vaccines.
HOUSING AND MORTGAGE CYCLE
Financials are currently selling at low price to earnings ratios and a steeper yield curve would provide a strong tailwind for banks, mortgage REITs, and mortgage servicing companies, many of which sell below book value. Low money rates out to 2023 set up a good backdrop for strong profit margins in the business of agency holdings and credit, the fuel for profit growth among REITs. The Fed’s constant purchasing of mortgage-backed assets sustains the value of REIT holdings and the Fed’s low money rate policies set up a profit margin sweet spot for REITs which own mostly agency paper and mortgages.
U.S. housing and the mortgage markets which finance it are booming, yet the stocks of companies that originate and service mortgages and the title insurers sell at a depressed 5-7 times earnings. That would be a reasonable valuation if the housing cycle was peaking but at the beginning of a cycle that could last years, we think both earnings and the multiples on those earnings can rise in the years ahead. Current demand is strong, and land purchased by builders is being immediately developed, not stockpiled for speculative purposes. Millennials, after years of hesitancy, are migrating from parents’ basements and beehive apartments to single-family residences. Supply will struggle to meet that demand. New building has been depressed for a decade and the baby boomers, who own 60% of the housing stock, are not moving. Since 90% of supply comes from existing homes, new construction will have to provide most of the new supply.
Annual Report | October 31, 2020 | 3 |
Clough Global Dividend and Income Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
FIXED INCOME
We continue to believe that a low interest rate world will continue to persist for the foreseeable future. We find duration an attractive hedge for the long equity book as well as a potential opportunity to produce positive returns. The Fund continues to hold long duration U.S. Treasuries as well as 10- to 30-year highly rated corporate bonds in sectors that are not adversely impacted by the pandemic.
CORPORATE UPDATE
By way of a team update, we are very pleased to announce that Dr. Noelle Tune, M.D. has joined Clough Capital Partners L.P. ("Clough Capital") as a Director. Noelle earned her B.A. from Harvard College where she was captain of the women’s crew team. She graduated from medical school at University of North Carolina Chapel Hill before completing her residency at Indiana University, where she was a Chief Resident. Importantly, Mike Hearle worked directly with Dr. Tune in equity research at what is now SVB Leerink from 2000-2004 and has seen the quality of her analysis firsthand. She is an accomplished equity analyst in her own right with a unique combination of talents and is a timely addition to our research efforts. Most recently, Noelle has been on the frontline of the fight against COVID-19 in her capacity as an emergency medicine physician at a high-volume urban health center where she has treated countless patients infected with the virus. Dr. Tune will focus on covering public and private investments in the therapeutics and services areas.
As always, please don’t hesitate to reach out to us with any questions or comments.
Sincerely,
Charles I Clough, Jr.
Robert M. Zdunczyk
This letter is provided for informational purposes only and is not an offer to purchase or sell shares. Clough Global Dividend and Income Fund (the “Fund”) is a closed-end fund, which is traded on the NYSE American LLC, and does not continuously issue shares for sale as open-end mutual funds do. The market price of a closed-end fund is based on the market’s value.
Although not generally stated throughout, the information in this letter reflects the opinions of the individual portfolio managers, which opinion is subject to change, and is not intended to be a forecast of future events, a guarantee of future results or investment advice.
The MSCI World Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of 23 developed markets countries. Both indices referenced herein reflect the reinvestment of dividends. Effective July 31, 2010, the MSCI World Index returns prior to January 1, 2002 were revised to reflect the total returns, with dividends reinvested, reported by MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).
4 | www.cloughglobal.com |
Clough Global Dividend and Income Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
The Bloomberg Barclays US Aggregate Bond Index measures the performance of the U.S. investment grade bond market. The Barclays Aggregate Bond index invests in a wide spectrum of public, investment-grade, taxable, fixed income securities in the United States, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities, all with maturities of more than 1 year.
The performance of the indices referenced herein is used for informational purposes only. One cannot invest directly in an index. Indices are not subject to any of the fees or expenses to which the Fund is subject, and there are significant differences between the Fund’s investments and the components of the indices referenced.
The net asset value (NAV) of a closed-end fund is the market price of the underlying investments (i.e., stocks and bonds) in the fund’s portfolio, minus liabilities, divided by the total number of fund shares outstanding. However, the fund also has a market price; the value of which it trades on an exchange. This market price can be more or less than its NAV.
RISKS
An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain an annual report or semiannual report which contains this and other information visit www.cloughglobal.com or call 1-877-256-8445. Read them carefully before investing.
A Fund’s distribution policy will, under certain circumstances, have certain adverse consequences to the Fund and its shareholders because it may result in a return of capital resulting in less of a shareholder’s assets being invested in the Fund and, over time, increase the Fund’s expense ratio.
Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. Based on current estimates, we anticipate the most recent distribution has been paid from short-term and longterm capital gains. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.
A Fund’s investments in securities of foreign issuers are subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues.
A Fund’s investments in preferred stocks and bonds of below investment grade quality (commonly referred to as “high yield” or “junk bonds”), if any, are predominately speculative because of the credit risk of their issuers.
An investment by a Fund in REITs will subject it to various risks. The first, real estate industry risk, is the risk that the REIT share prices will decline because of adverse developments affecting the real estate industry and real property values. In general, real estate values can be affected by a variety of factors, including supply and demand for properties, the economic health of the country or of different regions, and the strength of specific industries that rent properties. The second, investment style risk, is the risk that returns from REITs—which typically are small or medium capitalization stocks—will trail returns from the overall stock market. The third, interest rate risk, is the risk that changes in interest rates may hurt real estate values or make REIT shares less attractive than other income-producing investments. Credit risk is the risk that an issuer of a preferred or debt security will become unable to meet its obligation to make dividend, interest and principal payments.
Interest rate risk is the risk that preferred stocks paying fixed dividend rates and fixed-rate debt securities will decline in value because of changes in market interest rates. When interest rates rise the value of such securities generally will fall. Derivative transactions (such as futures contracts and options thereon, options, swaps, and short sales) subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Compared to investment companies that focus only on large companies, the Fund’s share price may be more volatile because it also invests in small and medium capitalization companies.
Past performance is neither a guarantee, nor necessarily indicative, of future results, which may be significantly affected by changes in economic and other conditions.
Annual Report | October 31, 2020 | 5 |
Clough Global Dividend and Income Fund | Portfolio Allocation |
October 31, 2020 (Unaudited)
Top 10 Equity Holdings(a)(d) | % of Total Portfolio |
1. PennyMac Financial Services, Inc. | 5.19% |
2. Quest Diagnostics, Inc. | 4.35% |
3. Apple, Inc. | 4.14% |
4. Community Healthcare Trust, Inc. | 4.09% |
5. Microsoft Corp. | 3.82% |
6. Taiwan Semiconductor Manufacturing Co., Ltd. | 2.53% |
7. First American Financial Corp. | 2.48% |
8. Annaly Capital Management, Inc. | 2.43% |
9. Sany Heavy Industry Co., Ltd. | 2.27% |
10. AGNC Investment Corp. | 2.06% |
Asset Allocation(a) | % of Total Portfolio |
Common Stock - US | 37.03% |
Common Stock - Foreign | 14.93% |
Total Return Swap Contracts | 3.98% |
Total Equities | 55.94% |
Government L/T | 21.24% |
Corporate Debt | 14.22% |
Preferred Stock | 0.85% |
Municipal Bond | 0.59% |
Asset-Backed Securities | 0.05% |
Total Fixed Income | 36.95% |
Short-Term Investments | 3.15% |
Futures | 1.80% |
Other (Cash) | 1.66% |
Purchased Options | 0.50% |
TOTAL INVESTMENTS | 100.00% |
Country Allocation(c) |
Long
Exposure %TNA |
Short
Exposure %TNA |
Gross
Exposure %TNA |
Net
Exposure %TNA |
United States | 121.5% | -2.6% | 124.1% | 118.9% |
U.S. Multinationals(b) | 22.2% | -5.1% | 27.3% | 17.1% |
China | 9.4% | 0.0% | 9.4% | 9.4% |
Taiwan | 3.8% | 0.0% | 3.8% | 3.8% |
Hong Kong | 3.2% | 0.0% | 3.2% | 3.2% |
South Korea | 1.1% | 0.0% | 1.1% | 1.1% |
Switzerland | 0.7% | -0.6% | 1.3% | 0.1% |
Other | 0.8% | -3.1% | 3.9% | -2.3% |
TOTAL INVESTMENTS | 162.7% | -11.5% | 174.1% | 151.3% |
(a) | Percentages calculated based on total portfolio, including securities sold short, cash balances, market value of futures, and notional value of return swaps. |
(b) | U.S. Multinationals includes companies organized or located in the United States that have more than 50% of revenues derived outside of the United States. |
(c) | Percentages calculated based on the net asset value of the Fund. |
(d) | Only long equity and equity-related positions are listed. |
6 | www.cloughglobal.com |
Clough Global Equity Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
For the fiscal year ending October 31, 2020, the Clough Global Equity Fund (“GLQ” or the “Fund”) was up 11.55% on net asset value (“NAV”) and up 3.21% on market price. The Fund’s benchmark, the MSCI World Index, was up 4.95% for the same period.
TOP FIVE CONTRIBUTORS AND DETRACTORS FOR THE YEAR
The Fund’s investment in Eurodollar futures as a hedge against a slowing global economy due to the emerging pandemic proved to be the largest contributor to performance for the year. Eurodollar futures, which are a proxy for future central bank policy, allowed the fund to maintain its long equity book in the turbulent months of February and March while participating in the recovery rally that started in April. The Fund continues to hold this position as an intended hedge against any additional slow down in economic activity from the spread of COVID-19.
PennyMac Financial Services Inc., a market dominant originator and servicer of residential and commercial mortgages, was a top contributor that benefited from increased refinance and new buyer activity as mortgage rates reached all time lows. Amazon.com Inc. and Netflix Inc. made significant gains from the COVID-19 driven shift to a stay at home economy. Finally, CRISPR Therapeutics, the leading company in the gene editing space, performed well as the company made progress in its oncology, beta thalassemia and sickle cell therapies.
Financial stocks were the top detractors for the year. Citigroup Inc., along with mortgage real estate investment trust (“REIT”) PennyMac Mortgage Investment Trust, Ladder Capital Corp. and Two Harbors Investment Corp., all declined as the markets priced in meaningful losses to the companies’ portfolios due to the sudden collapse in economy from COVID-19 related shutdowns. Finally, as the markets recovered in the spring, a hedge position in a S&P 500 Index exchange traded fund (“ETF”) was also top detractor from performance.
ON THE MARKETS: LIQUIDITY SUPPORT FOR EQUITIES IS POSITIVE
We are not political experts, but it appears equities have embraced a Biden presidency along with the possibility of a small Republican majority in the Senate and we can understand why. It is widely expected that there will be better coordination between a Biden administration and the Federal Reserve (the “Fed”) in combining monetary and fiscal policies. A Biden administration is expected to push for additional stimulus packages, and we assume will appoint dovish Federal Reserve governors.
The coronavirus was more of an exogenous shock to the market than would be a natural recession. There was no credit crisis or banking collapse, nor was there a profit hit from an excessive capacity build which destroys profitability in a key economic sector, like technology in 2000 or housing in 2008. The threat of more infections would likely prolong the policies of monetary ease.
The Fed is currently pumping liquidity into a growing economy and if it lives up to its promises of sustaining zero nominal interest rates into 2022 or 2023, the likelihood of higher returns on investment in the economy in 2021 and beyond looks pretty good.
In the meantime, investors are positioned defensively, holding $4.5 trillion in money market funds and another $15.7 trillion in short-term deposits. The amount of money sitting at the 90-day rate is close to the nominal gross domestic product (“GDP”). The Fed would like to see that money invested in the economy and is making holding that cash very costly.
The Fed is the most critical factor to the markets. Financial conditions are incredibly favorable, earnings expectations are rising, and the Fed continues to add reserves to the banking system. All of that is positive for equities.
Finally, businesses continue to generate large amounts of cash flow according to Bloomberg. Because business investment has been well below that spent in previous business expansions, businesses did not over invest, and excess capacity was never built, so pricing and profitability have held up. With the Pfizer vaccine likely to begin distribution over the next few months, we believe 2021 could be a very strong year for equities.
POSITIONING FOR 2021
The majority of the Fund’s current long exposure is focused in the high free cash flow generating sectors of technology and healthcare in the United States as well as in China. The Fund is also set up to potentially benefit from what we believe will be a long-lasting housing cycle in the U.S.
TECHNOLOGY
Looking ahead through the 2020s, we believe that the global buildout of 5G telecommunications networks will be a significant investment opportunity. All of the imaginative projects of the 2020s such as autonomous driving, machine learning and the “Internet of Things” require 5G technology. The 5G rollout accelerated with Apple’s announcement of a suite of its 5G equipped iPhones, which promise faster download and upload speeds, higher latency, and quality video gaming and streaming as enticements to buy the phones. Consumer spending is being diverted from travel and leisure to consumer electronics and evidence is mounting that affluent consumers will buy high-end phones. So far, 5G is widely available only in the Asia Pacific region, but where it is available selling prices are 15-20% higher than those of 4G equipped phones. Even in areas where 5G is not available, new phones are selling at a 7% premium to earlier generations.
Annual Report | October 31, 2020 | 7 |
Clough Global Equity Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
Hundreds of billions of dollars will be spent building out 5G, and competition will be intense, particularly among service providers and companies which build the commodity portions of the infrastructure. To be competitive, service providers will be forced to overbuild their networks ahead of demand and to discount their products to fill capacity. Handset manufacturers without the strong applications businesses which lock in customers, unlike Apple which does, will also have to price aggressively to sell their products. A move to a new standard could add $50-100 per phone to the materials bill, especially for radio frequency (“RF”) chips, processing power and added memory. High-end phone modems must be able to work with any phone in any market and that is expensive. For example, the cost of the modem alone in 5G can increase by more than 50%. So, it is necessary to answer the question: who will capture the profits?
Higher materials costs mean more 5G dollars will go to the supply chain companies which solve the bottlenecks, the parts of the networks where proprietary technology breakthroughs are critical to making 5G work. The semiconductor companies with the technologies that solve those problems will not only capture a larger percentage of the phone’s value, but also should lock in the highest profit margins.
A major barrier to entry in semiconductor manufacturing is a sharp rise in the capital intensity of component manufacturing. Taiwan Semiconductor Manufacturing Co Ltd. (“TSMC”), a current holding in the Fund, is expected to invest $130 billion through 2030 for high-end foundries for processor chips, an area where the company is already dominant. As capital intensity in the semiconductor industry rises, TSMC gains scale from share gains, and assumes pricing power and market share. Its foundry capacity is ten times that of Samsung’s and Chinese foundries barely compete in the space. TSMC has leading edge semiconductor design and production to the point that the company has already captured the leadership in processors from Intel Corp., and it already produces 20% of Intel’s sales. TSMC, with the industry’s first five nanometer A14 bionic chip, will provide the processors for all of Apple’s models offering speeds of up to 50% faster. Yet the stock has underperformed, and we believe it is relatively inexpensive.
We have particularly focused on companies that make up the Apple supply chain. For example, Skyworks Solutions Inc. is a manufacturer of RF chips whose products might be expected to capture a larger percentage of the iPhone’s revenues. Prior to 4G, radio frequency content per phone was about $10 for each smartphone. That rose to $20-30 per phone for 4G and will likely reach $35-40 for each 5G phone. Approximately 50% of the company’s revenues are from Apple.
Samsung Electronics Co Ltd. is also a current holding in the Fund. In memory and non-memory chips, the company has unexcelled research and development (“R&D”) and only trails Huawei Technologies Co Ltd. in announced patents. Now the company is making inroads into the manufacturing of 5G infrastructure, including high-end image sensors and foundry capacity. Its share of the telecom market, once a modest 4% or so for 4G, has risen to 10-15% for 5G. Not only is the company picking up on Huawei’s decline, but it has a secure supply chain located in Vietnam and South Korea. It has little China exposure and has far stronger R&D than either LM Ericsson or Nokia Oyj. The company successfully picked up a key Verizon 5G contract to supply 5G radio access equipment through 2025. Yet the stock sells at roughly book value, 11x 2021 earnings per share, offers a 3.5% yield, and its roughly $300 billion market capitalization includes $94 billion in cash.
HEALTHCARE
In our view, health sciences will be one of the fastest growing areas of spending in the 2020s. Investors have been jittery since Hillary Clinton, as a presidential candidate in 2015, pushed price controls for big pharma and biotech. Since then, tens of billions of R&D dollars have been spent developing new therapies and huge strides have been made in medical discoveries and genomics. Many of those therapies are now entering human trials and that is the point at which value can be created for many companies. The industry offers the cheapest source of R&D in the securities markets. There are three ways to monetize this as we currently see it:
1. | We anticipate a pickup in mergers and acquisitions (“M&A”). Only three deals were announced in the first half of 2020. In the third quarter, Gilead Sciences Inc. offered $21 billion for Immunomedics Inc. and Johnson and Johnson offered $6.5 billion for Momenta Pharmaceuticals Inc. We believe there exists significant pent-up demand at large pharma companies for attractive pipeline assets. The Fund is invested in potential biotechnology M&A targets that we believe generally have strong management teams, that have sold companies in the past, possess solid intellectual property, and disruptive technologies and attractive therapeutic focuses (e.g., oncology and rare diseases). |
2. | COVID-19 has created significant business opportunities for innovative healthcare companies, but a successful vaccine may not be the only positive advancement. In our view, telemedicine and pharmaceutical testing may actually present some of the best long-term profit opportunities. COVID-19 accelerated the shift to telemedicine from in-office visits and Teladoc Health Inc., the largest company in the telemedicine space, is a current holding in the Fund. Meanwhile, testing is becoming one of the fastest growing sectors in healthcare. We think the market underappreciates the critical role testing companies will continue to play, even with a vaccine approval. The Fund’s testing-related holdings include Hologic Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc. It should also be noted that Thermo Fisher is a leading producer of the refrigeration required for newly announced COVID-19 vaccines. |
8 | www.cloughglobal.com |
Clough Global Equity Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
3. | Additional core holdings include CRISPR Therapeutics, which made further progress demonstrating clinical progress in sickle cell disease, beta thalassemia and solid tumor trials and has partnered with Vertex Pharmaceuticals Inc. in a series of oncology trials. CRISPR has resumed dosing hemophilia patients for phase 1/2 trials and patients have remained blood transfusion free for 15, 9 and 5 months which are highly encouraging outcomes. On the oncology front, where the company fully owns its intellectual property, the company presented initial data for its phase 1-2 allogeneic CAR-T trial showing excellent activity and outcomes in this tough to treat population. |
HOUSING AND MORTGAGE CYCLE
Financials are currently selling at low price to earnings ratios and a steeper yield curve would provide a strong tailwind for banks, mortgage REITs, and mortgage servicing companies, many of which sell below book value. Low money rates out to 2023 set up a good backdrop for strong profit margins in the business of agency holdings and credit, the fuel for profit growth among REITs. The Fed’s constant purchasing of mortgage-backed assets sustains the value of REIT holdings and the Fed’s low money rate policies set up a profit margin sweet spot for REITs which own mostly agency paper and mortgages.
U.S. housing and the mortgage markets which finance it are booming, yet the stocks of companies that originate and service mortgages and the title insurers sell at a depressed 5-7 times earnings. That would be a reasonable valuation if the housing cycle was peaking but at the beginning of a cycle that could last years, we think both earnings and the multiples on those earnings can rise in the years ahead. Current demand is strong, and land purchased by builders is being immediately developed, not stockpiled for speculative purposes. Millennials, after years of hesitancy, are migrating from parents’ basements and beehive apartments to single-family residences. Supply will struggle to meet that demand. New building has been depressed for a decade and the baby boomers, who own 60% of the housing stock, are not moving. Since 90% of supply comes from existing homes, new construction will have to provide most of the new supply.
CORPORATE UPDATE
By way of a team update, we are very pleased to announce that Dr. Noelle Tune, M.D. has joined Clough Capital Partners L.P. ("Clough Capital") as a Director. Noelle earned her B.A. from Harvard College where she was captain of the women’s crew team. She graduated from medical school at University of North Carolina Chapel Hill before completing her residency at Indiana University, where she was a Chief Resident. Importantly, Mike Hearle worked directly with Dr. Tune in equity research at what is now SVB Leerink from 2000-2004 and has seen the quality of her analysis firsthand. She is an accomplished equity analyst in her own right with a unique combination of talents and is a timely addition to our research efforts. Most recently, Noelle has been on the frontline of the fight against COVID-19 in her capacity as an emergency medicine physician at a high-volume urban health center where she has treated countless patients infected with the virus. Dr. Tune will focus on covering public and private investments in the therapeutics and services areas.
As always, please don’t hesitate to reach out to us with any questions or comments.
Sincerely,
Charles I Clough, Jr.
Robert M. Zdunczyk
This letter is provided for informational purposes only and is not an offer to purchase or sell shares. Clough Global Equity Fund (the “Fund”) is a closed-end fund, which is traded on the NYSE American LLC, and does not continuously issue shares for sale as open-end mutual funds do. The market price of a closed-end fund is based on the market’s value.
Although not generally stated throughout, the information in this letter reflects the opinions of the individual portfolio managers, which opinion is subject to change, and is not intended to be a forecast of future events, a guarantee of future results or investment advice.
Annual Report | October 31, 2020 | 9 |
Clough Global Equity Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
The MSCI World Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of 23 developed markets countries. Both indices referenced herein reflect the reinvestment of dividends. Effective July 31, 2010, the MSCI World Index returns prior to January 1, 2002 were revised to reflect the total returns, with dividends reinvested, reported by MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).
The performance of the indices referenced herein is used for informational purposes only. One cannot invest directly in an index. Indices are not subject to any of the fees or expenses to which the Fund is subject, and there are significant differences between the Fund’s investments and the components of the indices referenced.
The net asset value (NAV) of a closed-end fund is the market price of the underlying investments (i.e., stocks and bonds) in the fund’s portfolio, minus liabilities, divided by the total number of fund shares outstanding. However, the fund also has a market price; the value of which it trades on an exchange. This market price can be more or less than its NAV.
RISKS
An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain an annual report or semiannual report which contains this and other information visit www.cloughglobal.com or call 1-877-256-8445. Read them carefully before investing.
A Fund’s distribution policy will, under certain circumstances, have certain adverse consequences to the Fund and its shareholders because it may result in a return of capital resulting in less of a shareholder’s assets being invested in the Fund and, over time, increase the Fund’s expense ratio.
Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. Based on current estimates, we anticipate the most recent distribution has been paid from short-term and longterm capital gains. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.
A Fund’s investments in securities of foreign issuers are subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues.
A Fund’s investments in preferred stocks and bonds of below investment grade quality (commonly referred to as “high yield” or “junk bonds”), if any, are predominately speculative because of the credit risk of their issuers.
An investment by a Fund in REITs will subject it to various risks. The first, real estate industry risk, is the risk that the REIT share prices will decline because of adverse developments affecting the real estate industry and real property values. In general, real estate values can be affected by a variety of factors, including supply and demand for properties, the economic health of the country or of different regions, and the strength of specific industries that rent properties. The second, investment style risk, is the risk that returns from REITs—which typically are small or medium capitalization stocks—will trail returns from the overall stock market. The third, interest rate risk, is the risk that changes in interest rates may hurt real estate values or make REIT shares less attractive than other income-producing investments. Credit risk is the risk that an issuer of a preferred or debt security will become unable to meet its obligation to make dividend, interest and principal payments.
Interest rate risk is the risk that preferred stocks paying fixed dividend rates and fixed-rate debt securities will decline in value because of changes in market interest rates. When interest rates rise the value of such securities generally will fall. Derivative transactions (such as futures contracts and options thereon, options, swaps, and short sales) subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Compared to investment companies that focus only on large companies, the Fund’s share price may be more volatile because it also invests in small and medium capitalization companies.
Past performance is neither a guarantee, nor necessarily indicative, of future results, which may be significantly affected by changes in economic and other conditions.
10 | www.cloughglobal.com |
Clough Global Equity Fund | Portfolio Allocation |
October 31, 2020 (Unaudited)
Top 10 Equity Holdings(a)(d) | % of Total Portfolio |
1. PennyMac Financial Services, Inc. | 4.69% |
2. First American Financial Corp. | 2.64% |
3. Taiwan Semiconductor Manufacturing Co., Ltd. | 2.47% |
4. Quest Diagnostics, Inc. | 2.46% |
5. Apple, Inc. | 2.37% |
6. Annaly Capital Management, Inc. | 2.34% |
7. AGNC Investment Corp. | 2.32% |
8. Hologic, Inc. | 2.18% |
9. Amazon.com, Inc. | 1.95% |
10. Sany Heavy Industry Co., Ltd. | 1.90% |
Asset Allocation(a) | % of Total Portfolio |
Common Stock - US | 56.44% |
Common Stock - Foreign | 22.76% |
Total Return Swap Contracts | 5.03% |
Total Equities | 84.23% |
Government L/T | 10.16% |
Total Fixed Income | 10.16% |
Other (Cash) | 1.78% |
Futures | 1.63% |
Short-Term Investments | 1.31% |
Purchased Options | 0.89% |
TOTAL INVESTMENTS | 100.00% |
Country Allocation(c) |
Long Exposure %TNA |
Short Exposure %TNA |
Gross Exposure %TNA |
Net Exposure %TNA |
United States | 109.7% | -2.5% | 112.2% | 107.2% |
U.S. Multinationals(b) | 22.5% | -4.8% | 27.3% | 17.7% |
China | 14.0% | 0.0% | 14.0% | 14.0% |
Taiwan | 3.7% | 0.0% | 3.7% | 3.7% |
Switzerland | 3.2% | -0.6% | 3.8% | 2.6% |
Hong Kong | 1.9% | 0.0% | 1.9% | 1.9% |
United Kingdom | 1.7% | 0.0% | 1.7% | 1.7% |
Canada | 1.5% | 0.0% | 1.5% | 1.5% |
Japan | 0.9% | 0.0% | 0.9% | 0.9% |
Other | 0.8% | -2.8% | 3.6% | -2.0% |
TOTAL INVESTMENTS | 159.9% | -10.7% | 170.6% | 149.2% |
(a) | Percentages calculated based on total portfolio, including securities sold short, cash balances, market value of futures, and notional value of return swaps. |
(b) | U.S. Multinationals includes companies organized or located in the United States that have more than 50% of revenues derived outside of the United States. |
(c) | Percentages calculated based on the net asset value of the Fund. |
(d) | Only long equity and equity-related positions are listed. |
Annual Report | October 31, 2020 | 11 |
Clough Global Opportunities Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
For the fiscal year ending October 31, 2020, the Clough Global Opportunities Fund (“GLO” or the “Fund”) was up 11.91% on net asset value (“NAV”) and up 8.46% on market price. The Fund’s benchmark, 75% MSCI World Index/25% of the Bloomberg Barclay U.S. Aggregate Bond Index, was up 5.73% for the same period.
TOP FIVE CONTRIBUTORS AND DETRACTORS FOR THE YEAR
The Fund’s investment in Eurodollar futures as a hedge against a slowing global economy due to the emerging pandemic proved to be the largest contributor to performance for the year. Eurodollar futures, which are a proxy for future central bank policy, allowed the Fund to maintain its long equity book in the turbulent months of February and March while participating in the recovery rally that started in April. The Fund continues to hold this position as an intended hedge against any additional slow down in economic activity from the spread of COVID-19.
PennyMac Financial Services Inc., a market dominant originator and servicer of residential and commercial mortgages, was a top contributor that benefited from increased refinance and new buyer activity as mortgage rates reached all time lows. Amazon.com Inc. and Teladoc Health Inc., a leading online healthcare provider, made significant gains from the COVID-19 driven shift to a stay at home economy. Finally, CRISPR Therapeutics, the leading company in the gene editing space, performed well as the company made progress in its oncology, beta thalassemia and sickle cell therapies.
Financial stocks were the top detractors for the year. Citigroup Inc., along with mortgage real estate investment trust (“REIT”) PennyMac Mortgage Investment Trust and Two Harbors Investment Corp., all declined as the markets priced in meaningful losses to the companies’ portfolios due to the sudden collapse in economy from COVID-19 related shutdowns. Finally, as the markets recovered in the spring, hedge positions in a S&P 500 Index exchange traded fund (“ETF”) and options on the S&P 500 Index were also top detractors from performance.
ON THE MARKETS: LIQUIDITY SUPPORT FOR EQUITIES IS POSITIVE
We are not political experts, but it appears equities have embraced a Biden presidency along with the possibility of a small Republican majority in the Senate and we can understand why. It is widely expected that there will be better coordination between a Biden administration and the Federal Reserve (the “Fed”) in combining monetary and fiscal policies. A Biden administration is expected to push for additional stimulus packages, and we assume will appoint dovish Federal Reserve governors.
The coronavirus was more of an exogenous shock to the market than would be a natural recession. There was no credit crisis or banking collapse, nor was there a profit hit from an excessive capacity build which destroys profitability in a key economic sector, like technology in 2000 or housing in 2008. The threat of more infections would likely prolong the policies of monetary ease.
The Fed is currently pumping liquidity into a growing economy and if it lives up to its promises of sustaining zero nominal interest rates into 2022 or 2023, the likelihood of higher returns on investment in the economy in 2021 and beyond looks pretty good.
In the meantime, investors are positioned defensively, holding $4.5 trillion in money market funds and another $15.7 trillion in short-term deposits. The amount of money sitting at the 90-day rate is close to the nominal gross domestic product (“GDP”). The Fed would like to see that money invested in the economy and is making holding that cash very costly.
The Fed is the most critical factor to the markets. Financial conditions are incredibly favorable, earnings expectations are rising, and the Fed continues to add reserves to the banking system. All of that is positive for equities.
Finally, businesses continue to generate large amounts of cash flow according to Bloomberg. Because business investment has been well below that spent in previous business expansions, businesses did not over invest, and excess capacity was never built, so pricing and profitability have held up. With the Pfizer vaccine likely to begin distribution over the next few months, we believe 2021 could be a very strong year for equities.
POSITIONING FOR 2021
The majority of the Fund’s current long exposure is focused in the high free cash flow generating sectors of technology and healthcare in the United States as well as in China. The Fund is also set up to potentially benefit from what we believe will be a long-lasting housing cycle in the U.S.
TECHNOLOGY
Looking ahead through the 2020s, we believe that the global buildout of 5G telecommunications networks will be a significant investment opportunity. All of the imaginative projects of the 2020s such as autonomous driving, machine learning and the “Internet of Things” require 5G technology. The 5G rollout accelerated with Apple’s announcement of a suite of its 5G equipped iPhones, which promise faster download and upload speeds, higher latency, and quality video gaming and streaming as enticements to buy the phones. Consumer spending is being diverted from travel and leisure to consumer electronics and evidence is mounting that affluent consumers will buy high-end phones. So far, 5G is widely available only in the Asia Pacific region, but where it is available selling prices are 15-20% higher than those of 4G equipped phones. Even in areas where 5G is not available, new phones are selling at a 7% premium to earlier generations.
12 | www.cloughglobal.com |
Clough Global Opportunities Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
Hundreds of billions of dollars will be spent building out 5G, and competition will be intense, particularly among service providers and companies which build the commodity portions of the infrastructure. To be competitive, service providers will be forced to overbuild their networks ahead of demand and to discount their products to fill capacity. Handset manufacturers without the strong applications businesses which lock in customers, unlike Apple which does, will also have to price aggressively to sell their products. A move to a new standard could add $50-100 per phone to the materials bill, especially for radio frequency (“RF”) chips, processing power and added memory. High-end phone modems must be able to work with any phone in any market and that is expensive. For example, the cost of the modem alone in 5G can increase by more than 50%. So, it is necessary to answer the question: who will capture the profits?
Higher materials costs mean more 5G dollars will go to the supply chain companies which solve the bottlenecks, the parts of the networks where proprietary technology breakthroughs are critical to making 5G work. The semiconductor companies with the technologies that solve those problems will not only capture a larger percentage of the phone’s value, but also should lock in the highest profit margins.
A major barrier to entry in semiconductor manufacturing is a sharp rise in the capital intensity of component manufacturing. Taiwan Semiconductor Manufacturing Co Ltd. (“TSMC”), a current holding in the Fund, is expected to invest $130 billion through 2030 for high-end foundries for processor chips, an area where the company is already dominant. As capital intensity in the semiconductor industry rises, TSMC gains scale from share gains, and assumes pricing power and market share. Its foundry capacity is ten times that of Samsung’s and Chinese foundries barely compete in the space. TSMC has leading edge semiconductor design and production to the point that the company has already captured the leadership in processors from Intel Corp., and it already produces 20% of Intel’s sales. TSMC, with the industry’s first five nanometer A14 bionic chip, will provide the processors for all of Apple’s models offering speeds of up to 50% faster. Yet the stock has underperformed, and we believe it is relatively inexpensive.
We have particularly focused on companies that make up the Apple supply chain. For example, Skyworks Solutions Inc. is a manufacturer of RF chips whose products might be expected to capture a larger percentage of the iPhone’s revenues. Prior to 4G, radio frequency content per phone was about $10 for each smartphone. That rose to $20-30 per phone for 4G and will likely reach $35-40 for each 5G phone. Approximately 50% of the company’s revenues are from Apple.
Samsung Electronics Co Ltd. is also a current holding in the Fund. In memory and non-memory chips, the company has unexcelled research and development (“R&D”) and only trails Huawei Technologies Co Ltd. in announced patents. Now the company is making inroads into the manufacturing of 5G infrastructure, including high-end image sensors and foundry capacity. Its share of the telecom market, once a modest 4% or so for 4G, has risen to 10-15% for 5G. Not only is the company picking up on Huawei’s decline, but it has a secure supply chain located in Vietnam and South Korea. It has little China exposure and has far stronger R&D than either LM Ericsson or Nokia Oyj. The company successfully picked up a key Verizon 5G contract to supply 5G radio access equipment through 2025. Yet the stock sells at roughly book value, 11x 2021 earnings per share, offers a 3.5% yield, and its roughly $300 billion market capitalization includes $94 billion in cash.
HEALTHCARE
In our view, health sciences will be one of the fastest growing areas of spending in the 2020s. Investors have been jittery since Hillary Clinton, as a presidential candidate in 2015, pushed price controls for big pharma and biotech. Since then, tens of billions of R&D dollars have been spent developing new therapies and huge strides have been made in medical discoveries and genomics. Many of those therapies are now entering human trials and that is the point at which value can be created for many companies. The industry offers the cheapest source of R&D in the securities markets. There are three ways to monetize this as we currently see it:
1. | We anticipate a pickup in mergers and acquisitions (“M&A”). Only three deals were announced in the first half of 2020. In the third quarter, Gilead Sciences Inc. offered $21 billion for Immunomedics Inc. and Johnson and Johnson offered $6.5 billion for Momenta Pharmaceuticals Inc. We believe there exists significant pent-up demand at large pharma companies for attractive pipeline assets. The Fund is invested in potential biotechnology M&A targets that we believe generally have strong management teams, that have sold companies in the past, possess solid intellectual property, and disruptive technologies and attractive therapeutic focuses (e.g., oncology and rare diseases). |
2. | COVID-19 has created significant business opportunities for innovative healthcare companies, but a successful vaccine may not be the only positive advancement. In our view, telemedicine and pharmaceutical testing may actually present some of the best long-term profit opportunities. COVID-19 accelerated the shift to telemedicine from in-office visits and Teladoc Health Inc., the largest company in the telemedicine space, is a current holding in the Fund. Meanwhile, testing is becoming one of the fastest growing sectors in healthcare. We think the market underappreciates the critical role testing companies will continue to play, even with a vaccine approval. The Fund’s testing-related holdings include Hologic Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Inc. It should also be noted that Thermo Fisher is a leading producer of the refrigeration required for newly announced COVID-19 vaccines. |
Annual Report | October 31, 2020 | 13 |
Clough Global Opportunities Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
3. | Additional core holdings include CRISPR Therapeutics, which made further progress demonstrating clinical progress in sickle cell disease, beta thalassemia and solid tumor trials and has partnered with Vertex Pharmaceuticals Inc. in a series of oncology trials. CRISPR has resumed dosing hemophilia patients for phase 1/2 trials and patients have remained blood transfusion free for 15, 9 and 5 months which are highly encouraging outcomes. On the oncology front, where the company fully owns its intellectual property, the company presented initial data for its phase 1-2 allogeneic CAR-T trial showing excellent activity and outcomes in this tough to treat population. |
HOUSING AND MORTGAGE CYCLE
Financials are currently selling at a low price to earnings ratios and a steeper yield curve would provide a strong tailwind for banks, mortgage REITs, and mortgage servicing companies, many of which sell below book value. Low money rates out to 2023 set up a good backdrop for strong profit margins in the business of agency holdings and credit, the fuel for profit growth among REITs. The Fed’s constant purchasing of mortgage-backed assets sustains the value of REIT holdings and the Fed’s low money rate policies set up a profit margin sweet spot for REITs which own mostly agency paper and mortgages.
U.S. housing and the mortgage markets which finance it are booming, yet the stocks of companies that originate and service mortgages and the title insurers sell at a depressed 5-7 times earnings. That would be a reasonable valuation if the housing cycle was peaking but at the beginning of a cycle that could last years, we think both earnings and the multiples on those earnings can rise in the years ahead. Current demand is strong, and land purchased by builders is being immediately developed, not stockpiled for speculative purposes. Millennials, after years of hesitancy, are migrating from parents’ basements and beehive apartments to single-family residences. Supply will struggle to meet that demand. New building has been depressed for a decade and the baby boomers, who own 60% of the housing stock, are not moving. Since 90% of supply comes from existing homes, new construction will have to provide most of the new supply.
FIXED INCOME
We continue to believe that a low interest rate world will continue to persist for the foreseeable future. We find duration an attractive hedge for the long equity book as well as a potential opportunity to produce positive returns for the Fund’s investors. The Fund continues to hold long duration U.S. Treasuries as well as 10- to 30-year highly rated corporate bonds in sectors that are not adversely impacted by the pandemic.
CORPORATE UPDATE
By way of a team update, we are very pleased to announce that Dr. Noelle Tune, M.D. has joined Clough Capital Partners L.P. ("Clough Capital") as a Director. Noelle earned her B.A. from Harvard College where she was captain of the women’s crew team. She graduated from medical school at University of North Carolina Chapel Hill before completing her residency at Indiana University, where she was a Chief Resident. Importantly, Mike Hearle worked directly with Dr. Tune in equity research at what is now SVB Leerink from 2000-2004 and has seen the quality of her analysis firsthand. She is an accomplished equity analyst in her own right with a unique combination of talents and is a timely addition to our research efforts. Most recently, Noelle has been on the frontline of the fight against COVID-19 in her capacity as an emergency medicine physician at a high-volume urban health center where she has treated countless patients infected with the virus. Dr. Tune will focus on covering public and private investments in the therapeutics and services areas.
As always, please don’t hesitate to reach out to us with any questions or comments.
Sincerely,
Charles I Clough, Jr.
Robert M. Zdunczyk
This letter is provided for informational purposes only and is not an offer to purchase or sell shares. Clough Opportunities Fund (the “Fund”) is a closed-end fund, which is traded on the NYSE American LLC, and does not continuously issue shares for sale as open-end mutual funds do. The market price of a closed-end fund is based on the market’s value.
Although not generally stated throughout, the information in this letter reflects the opinions of the individual portfolio managers, which opinion is subject to change, and is not intended to be a forecast of future events, a guarantee of future results or investment advice.
14 | www.cloughglobal.com |
Clough Global Opportunities Fund | Shareholder Letter |
October 31, 2020 (Unaudited)
The MSCI World Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of 23 developed markets countries. Both indices referenced herein reflect the reinvestment of dividends. Effective July 31, 2010, the MSCI World Index returns prior to January 1, 2002 were revised to reflect the total returns, with dividends reinvested, reported by MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an “as is” basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the “MSCI Parties”) expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages (www.msci.com).
The Bloomberg Barclays US Aggregate Bond Index measures the performance of the U.S. investment grade bond market. The Barclays Aggregate Bond index invests in a wide spectrum of public, investment-grade, taxable, fixed income securities in the United States, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities, all with maturities of more than 1 year.
The performance of the indices referenced herein is used for informational purposes only. One cannot invest directly in an index. Indices are not subject to any of the fees or expenses to which the Fund is subject, and there are significant differences between the Fund’s investments and the components of the indices referenced.
The net asset value (NAV) of a closed-end fund is the market price of the underlying investments (i.e., stocks and bonds) in the fund’s portfolio, minus liabilities, divided by the total number of fund shares outstanding. However, the fund also has a market price; the value of which it trades on an exchange. This market price can be more or less than its NAV.
RISKS
An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain an annual report or semiannual report which contains this and other information visit www.cloughglobal.com or call 1-877-256-8445. Read them carefully before investing.
A Fund’s distribution policy will, under certain circumstances, have certain adverse consequences to the Fund and its shareholders because it may result in a return of capital resulting in less of a shareholder’s assets being invested in the Fund and, over time, increase the Fund’s expense ratio.
Distributions may be paid from sources of income other than ordinary income, such as net realized short-term capital gains, net realized long-term capital gains and return of capital. Based on current estimates, we anticipate the most recent distribution has been paid from short-term and long-term capital gains. The actual amounts and sources of the amounts for tax reporting purposes will depend upon a Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. If a distribution includes anything other than net investment income, the Fund provides a Section 19(a) notice of the best estimate of its distribution sources at that time. These estimates may not match the final tax characterization (for the full year’s distributions) contained in shareholders’ 1099-DIV forms after the end of the year.
A Fund’s investments in securities of foreign issuers are subject to risks not usually associated with owning securities of U.S. issuers. These risks can include fluctuations in foreign currencies, foreign currency exchange controls, social, political and economic instability, differences in securities regulation and trading, expropriation or nationalization of assets, and foreign taxation issues.
A Fund’s investments in preferred stocks and bonds of below investment grade quality (commonly referred to as “high yield” or “junk bonds”), if any, are predominately speculative because of the credit risk of their issuers.
An investment by a Fund in REITs will subject it to various risks. The first, real estate industry risk, is the risk that the REIT share prices will decline because of adverse developments affecting the real estate industry and real property values. In general, real estate values can be affected by a variety of factors, including supply and demand for properties, the economic health of the country or of different regions, and the strength of specific industries that rent properties. The second, investment style risk, is the risk that returns from REITs—which typically are small or medium capitalization stocks—will trail returns from the overall stock market. The third, interest rate risk, is the risk that changes in interest rates may hurt real estate values or make REIT shares less attractive than other income-producing investments. Credit risk is the risk that an issuer of a preferred or debt security will become unable to meet its obligation to make dividend, interest and principal payments.
Interest rate risk is the risk that preferred stocks paying fixed dividend rates and fixed-rate debt securities will decline in value because of changes in market interest rates. When interest rates rise the value of such securities generally will fall. Derivative transactions (such as futures contracts and options thereon, options, swaps, and short sales) subject a Fund to increased risk of principal loss due to imperfect correlation or unexpected price or interest rate movements. Compared to investment companies that focus only on large companies, the Fund’s share price may be more volatile because it also invests in small and medium capitalization companies.
Past performance is neither a guarantee, nor necessarily indicative, of future results, which may be significantly affected by changes in economic and other conditions.
Annual Report | October 31, 2020 | 15 |
Clough Global Opportunities Fund | Portfolio Allocation |
October 31, 2020 (Unaudited)
Top 10 Equity Holdings(a)(d) | % of Total Portfolio |
1. PennyMac Financial Services, Inc. | 4.67% |
2. Taiwan Semiconductor Manufacturing Co., Ltd. | 2.49% |
3. Quest Diagnostics, Inc. | 2.48% |
4. First American Financial Corp. | 2.40% |
5. Apple, Inc. | 2.37% |
6. Annaly Capital Management, Inc. | 2.34% |
7. Hologic, Inc. | 2.18% |
8. AGNC Investment Corp. | 2.03% |
9. CRISPR Therapeutics AG | 1.96% |
10. Sany Heavy Industry Co., Ltd. | 1.93% |
Asset Allocation(a) | % of Total Portfolio |
Common Stock - US | 51.68% |
Common Stock - Foreign | 22.32% |
Total Return Swap Contracts | 5.07% |
Total Equities | 79.07% |
Government L/T | 12.01% |
Corporate Debt | 2.32% |
Municipal Bond | 0.47% |
Total Fixed Income | 14.80% |
Short-Term Investments | 1.92% |
Other (Cash) | 1.67% |
Futures | 1.64% |
Purchased Options | 0.90% |
TOTAL INVESTMENTS | 100.00% |
Country Allocation(c) |
Long Exposure %TNA |
Short Exposure %TNA |
Gross Exposure %TNA |
Net Exposure %TNA |
United States | 108.7% | -2.4% | 111.1% | 106.3% |
U.S. Multinationals(b) | 21.8% | -4.9% | 26.7% | 16.9% |
China | 15.5% | 0.0% | 15.5% | 15.5% |
Taiwan | 3.7% | 0.0% | 3.7% | 3.7% |
Switzerland | 3.3% | -0.6% | 3.9% | 2.7% |
Hong Kong | 1.9% | 0.0% | 1.9% | 1.9% |
United Kingdom | 1.7% | 0.0% | 1.7% | 1.7% |
Canada | 1.5% | 0.0% | 1.5% | 1.5% |
Japan | 0.9% | 0.0% | 0.9% | 0.9% |
Other | 0.8% | -3.0% | 3.8% | -2.2% |
TOTAL INVESTMENTS | 159.8% | -10.9% | 170.7% | 148.9% |
(a) | Percentages calculated based on total portfolio, including securities sold short, cash balances, market value of futures, and notional value of return swaps. |
(b) | U.S. Multinationals includes companies organized or located in the United States that have more than 50% of revenues derived outside of the United States. |
(c) | Percentages calculated based on the net asset value of the Fund. |
(d) | Only long equity and equity-related positions are listed. |
16 | www.cloughglobal.com |
Clough Global Dividend and Income Fund | Statement of Investments |
October 31, 2020
Shares | Value | |||||||
COMMON STOCKS 90.01% | ||||||||
Communication Services 1.49% | ||||||||
Tencent Holdings, Ltd. | 16,800 | $ | 1,280,722 | |||||
Consumer Discretionary 7.67% | ||||||||
DR Horton, Inc.(a)(b) | 38,600 | 2,578,866 | ||||||
Lennar Corp. - Class A(a)(b) | 34,800 | 2,444,004 | ||||||
Samsonite International S.A.(c) | 708,900 | 713,244 | ||||||
Xinyi Glass Holdings, Ltd. | 392,000 | 858,582 | ||||||
6,594,696 | ||||||||
Financials 32.23% | ||||||||
AGNC Investment Corp.(a) | 192,200 | 2,685,034 | ||||||
Annaly Capital Management, Inc.(a) | 446,600 | 3,166,394 | ||||||
Ares Capital Corp. | 30,200 | 417,666 | ||||||
Bank of America Corp.(a)(b) | 84,661 | 2,006,466 | ||||||
Barings BDC, Inc.(a) | 183,800 | 1,380,338 | ||||||
Citigroup, Inc.(a)(b) | 34,706 | 1,437,523 | ||||||
First American Financial Corp.(a)(b) | 72,300 | 3,223,857 | ||||||
Golub Capital BDC, Inc.(a) | 105,775 | 1,344,400 | ||||||
Hong Kong Exchanges and Clearing, Ltd. | 35,200 | 1,680,882 | ||||||
JPMorgan Chase & Co.(a)(b) | 13,200 | 1,294,128 | ||||||
PennyMac Financial Services, Inc.(a) | 133,000 | 6,759,060 | ||||||
Sixth Street Specialty Lending, Inc.(a)(b) | 94,400 | 1,553,824 | ||||||
Stewart Information Services Corp.(a) | 18,300 | 775,737 | ||||||
27,725,309 | ||||||||
Health Care 19.68% | ||||||||
AbbVie, Inc.(a) | 12,700 | 1,080,770 | ||||||
Amgen, Inc.(a)(b) | 7,879 | 1,709,270 | ||||||
Baxter International, Inc.(a)(b) | 10,900 | 845,513 | ||||||
Eli Lilly & Co.(a)(b) | 9,213 | 1,201,928 | ||||||
McKesson Corp. | 9,050 | 1,334,785 | ||||||
Quest Diagnostics, Inc.(a)(b) | 46,305 | 5,655,693 | ||||||
Thermo Fisher Scientific, Inc.(a)(b) | 4,776 | 2,259,621 | ||||||
Zimmer Biomet Holdings, Inc.(a)(b) | 6,090 | 804,489 | ||||||
Zoetis, Inc.(a)(b) | 12,855 | 2,038,160 | ||||||
16,930,229 | ||||||||
Information Technology 21.75% | ||||||||
Apple, Inc.(a)(b) | 49,515 | 5,390,203 | ||||||
Infineon Technologies AG | 23,959 | 666,900 | ||||||
Intuit, Inc.(a) | 2,505 | 788,273 | ||||||
Lam Research Corp.(a)(b) | 3,460 | 1,183,597 | ||||||
Mastercard, Inc. - Class A(a) | 2,269 | 654,924 | ||||||
Microsoft Corp.(a)(b) | 24,527 | 4,965,982 | ||||||
Samsung Electronics Co., Ltd. | 19,414 | 968,390 | ||||||
Skyworks Solutions, Inc.(a) | 5,690 | 803,940 | ||||||
Taiwan Semiconductor Manufacturing Co., Ltd. | 59,000 | 891,080 |
Shares | Value | |||||||
Information Technology (continued) | ||||||||
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(a)(b) | 28,600 | $ | 2,398,682 | |||||
18,711,971 | ||||||||
Real Estate 7.19% | ||||||||
Community Healthcare Trust, Inc.(a) | 115,000 | 5,324,500 | ||||||
Physicians Realty Trust(a) | 51,000 | 859,860 | ||||||
6,184,360 | ||||||||
TOTAL COMMON STOCKS | ||||||||
(Cost $66,654,029) | 77,427,287 | |||||||
PREFERRED STOCKS 1.29% | ||||||||
Gabelli Equity Trust, Inc. | ||||||||
Series K, Perpetual Maturity 5.000%(d) | 21,200 | 566,271 | ||||||
Trinity Capital, Inc., 01/16/2025 7.000%(a)(b)(e) | 22,400 | 543,760 | ||||||
TOTAL PREFERRED STOCKS | ||||||||
(Cost $1,090,000) | 1,110,031 | |||||||
Underlying Security/Expiration Date/Exercise Price/Notional Amount |
Contracts | Value | ||||||
PURCHASED OPTIONS 0.76% | ||||||||
Call Options Purchased 0.76% | ||||||||
CRISPR Therapeutics AG | ||||||||
01/15/21, $90, $2,111,860 | 230 | 355,350 | ||||||
Eurodollar Future Option | ||||||||
12/14/21, $100, $359,457,450 | 1,441 | 99,069 | ||||||
12/14/21, $99.875, $523,845,000 | 2,100 | 196,875 | ||||||
Total Call Options Purchased | ||||||||
(Cost $1,347,000) | 651,294 | |||||||
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
CORPORATE BONDS 18.08% | ||||||||
Agile Group Holdings, Ltd. | ||||||||
11/23/2020, 9.500%(f) | $ | 250,000 | 250,764 | |||||
Amazon.com, Inc. | ||||||||
06/03/2050, 2.500% | 1,000,000 | 989,912 | ||||||
Amgen, Inc. | ||||||||
02/21/2030, 2.450%(a)(b) | 400,000 | 421,996 | ||||||
Arrow Electronics, Inc. | ||||||||
01/12/2028, 3.875% | 300,000 | 333,543 | ||||||
Brown University in Providence in the State of Rhode Island and Providence Plant | ||||||||
Series A, 09/01/2050, 2.924% | 500,000 | 528,527 |
Annual Report | October 31, 2020 | 17 |
Clough Global Dividend and Income Fund | Statement of Investments |
October 31, 2020
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
CORPORATE BONDS (continued) | ||||||||
Carvana Co. | ||||||||
10/01/2028, 5.875%(e) | $ | 1,000,000 | $ | 988,960 | ||||
Centene Corp. | ||||||||
01/15/2025, 4.750% | 250,000 | 257,187 | ||||||
01/15/2025, 4.750%(a) | 160,000 | 164,600 | ||||||
Citrix Systems, Inc. | ||||||||
03/01/2030, 3.300% | 800,000 | 841,782 | ||||||
Commonwealth Edison Co. | ||||||||
03/01/2045, 3.700% | 500,000 | 573,741 | ||||||
Duke University | ||||||||
Series 2020, 10/01/2044, 2.682% | 300,000 | 306,441 | ||||||
Eli Lilly and Co. | ||||||||
03/15/2029, 3.375%(a)(b) | 400,000 | 461,388 | ||||||
09/15/2060, 2.500% | 500,000 | 467,060 | ||||||
Fidelity National Financial, Inc. | ||||||||
03/15/2031, 2.450% | 850,000 | 832,833 | ||||||
JPMorgan Chase & Co. | ||||||||
10/15/2030, 1D US SOFR + 1.51%(g) | 500,000 | 534,746 | ||||||
Lennar Corp. | ||||||||
01/15/2022, 4.125% | 450,000 | 461,531 | ||||||
Melco Resorts Finance, Ltd. | ||||||||
07/21/2028, 5.750%(e) | 250,000 | 249,442 | ||||||
Microchip Technology, Inc. | ||||||||
09/01/2023, 2.670%(e) | 500,000 | 519,154 | ||||||
Molson Coors Beverage Co. | ||||||||
07/15/2026, 3.000% | 300,000 | 322,655 | ||||||
Nestle Holdings, Inc. | ||||||||
09/24/2038, 3.900%(e) | 200,000 | 248,802 | ||||||
Prudential Financial, Inc. | ||||||||
12/07/2049, 3.935% | 500,000 | 566,765 | ||||||
PulteGroup, Inc. | ||||||||
03/01/2026, 5.500%(a) | 300,000 | 347,062 | ||||||
Regeneron Pharmaceuticals, Inc. | ||||||||
09/15/2030, 1.750% | 500,000 | 482,412 | ||||||
09/15/2050, 2.800% | 400,000 | 375,581 | ||||||
Solar Capital, Ltd. | ||||||||
01/20/2023, 4.500% | 500,000 | 506,442 | ||||||
Stanford Health Care | ||||||||
Series 2020, 08/15/2030, 3.310% | 300,000 | 336,129 | ||||||
Sunac China Holdings, Ltd. | ||||||||
04/19/2023, 8.350%(f) | 750,000 | 770,095 | ||||||
Times China Holdings, Ltd. | ||||||||
06/04/2021, 7.850%(f) | 500,000 | 505,287 | ||||||
Toll Brothers Finance Corp. | ||||||||
11/01/2029, 3.800%(a) | 500,000 | 532,420 | ||||||
University of Notre Dame du Lac | ||||||||
Series 2020, 02/15/2030, 1.637% | 300,000 | 301,728 | ||||||
University of Southern California | ||||||||
10/01/2039, 3.028% | 630,000 | 671,138 |
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
CORPORATE BONDS (continued) | ||||||||
Yale University | ||||||||
Series 2020, 04/15/2030, 1.482% | $ | 400,000 | $ | 401,487 | ||||
TOTAL CORPORATE BONDS | ||||||||
(Cost $15,656,123) | 15,551,610 | |||||||
CONVERTIBLE CORPORATE BONDS 3.43% | ||||||||
Ares Capital Corp. | ||||||||
02/01/2022, 3.750%(a)(b) | 550,000 | 554,400 | ||||||
Gossamer Bio, Inc. | ||||||||
06/01/2027, 5.000%(a)(b) | 1,070,000 | 877,082 | ||||||
Starwood Property Trust, Inc. | ||||||||
04/01/2023, 4.375% | 400,000 | 386,789 | ||||||
Teladoc Health, Inc. | ||||||||
06/01/2027, 1.250%(a)(b)(e) | 700,000 | 818,490 | ||||||
Two Harbors Investment Corp. | ||||||||
01/15/2022, 6.250% | 314,000 | 313,804 | ||||||
TOTAL CONVERTIBLE CORPORATE BONDS | ||||||||
(Cost $3,026,528) | 2,950,565 | |||||||
ASSET-BACKED SECURITIES 0.08% | ||||||||
United States Small Business Administration | ||||||||
Series 2008-20L, Class 1, 12/01/2028, 6.220%(a)(b) | 59,867 | 66,659 | ||||||
TOTAL ASSET-BACKED SECURITIES | ||||||||
(Cost $59,867) | 66,659 | |||||||
GOVERNMENT & AGENCY OBLIGATIONS 32.14% | ||||||||
U.S. Treasury Bonds | ||||||||
02/15/2050, 2.000%(a) | 3,000,000 | 3,248,437 | ||||||
05/15/2050, 1.250% | 550,000 | 496,719 | ||||||
08/15/2050, 1.375%(a) | 7,500,000 | 6,992,578 | ||||||
U.S. Treasury Notes | ||||||||
01/31/2021, 2.500% | 1,000,000 | 1,005,743 | ||||||
02/28/2025, 1.125%(a) | 5,900,000 | 6,105,578 | ||||||
03/31/2025, 2.625% | 2,700,000 | 2,971,266 | ||||||
02/28/2027, 1.125%(a) | 6,600,000 | 6,828,293 | ||||||
TOTAL GOVERNMENT & AGENCY OBLIGATIONS | ||||||||
(Cost $28,372,743) | 27,648,614 | |||||||
MUNICIPAL BONDS 0.89% | ||||||||
Massachusetts State College Building Authority, Higher Education Revenue Bonds | ||||||||
05/01/2040, 2.972% | 300,000 | 293,694 |
18 | www.cloughglobal.com |
Clough Global Dividend and Income Fund | Statement of Investments |
October 31, 2020
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
MUNICIPAL BONDS (continued) | ||||||||
University of Virginia, Higher Education Revenue Bonds | ||||||||
09/01/2050, 2.256% | $ | 500,000 | $ | 470,610 | ||||
TOTAL MUNICIPAL BONDS | ||||||||
(Cost $814,451) | 764,304 | |||||||
Shares | Value | |||||||
SHORT-TERM INVESTMENTS 4.77% | ||||||||
Money Market Funds 4.77% | ||||||||
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.040% 7-day yield) | 4,104,432 | 4,104,432 | ||||||
TOTAL SHORT-TERM INVESTMENTS | ||||||||
(Cost $4,104,432) | 4,104,432 | |||||||
Total Investments - 151.45% | ||||||||
(Cost $121,125,173) | 130,274,796 | |||||||
Liabilities in Excess of Other Assets - (51.45%)(h) | (44,258,738 | ) | ||||||
NET ASSETS - 100.00% | $ | 86,016,058 | ||||||
SCHEDULE OF SECURITIES SOLD SHORT(c) |
Shares | Value | ||||||
COMMON STOCKS (11.39%) | ||||||||
Consumer Discretionary (0.64%) | ||||||||
Vroom, Inc. | (13,400 | ) | (550,740 | ) | ||||
Financials (3.48%) | ||||||||
Deutsche Bank AG | (203,600 | ) | (1,883,300 | ) | ||||
Invesco, Ltd. | (28,500 | ) | (373,635 | ) | ||||
Mediobanca Banca di Credito Finanziario SpA | (40,686 | ) | (288,479 | ) | ||||
Societe Generale S.A. | (8,443 | ) | (114,457 | ) | ||||
UniCredit SpA | (44,837 | ) | (334,255 | ) | ||||
(2,994,126 | ) | |||||||
Health Care (1.65%) | ||||||||
Bruker Corp. | (14,100 | ) | (599,814 | ) | ||||
PRA Health Sciences, Inc. | (8,415 | ) | (819,958 | ) | ||||
(1,419,772 | ) | |||||||
Information Technology (5.62%) | ||||||||
Cree, Inc. | (18,600 | ) | (1,182,960 | ) | ||||
International Business Machines Corp. | (23,535 | ) | (2,627,918 | ) | ||||
Qualys, Inc. | (5,500 | ) | (483,175 | ) |
SCHEDULE OF SECURITIES SOLD SHORT(c) (continued) |
Shares | Value | ||||||
Information Technology (continued) | ||||||||
Temenos AG | (4,980 | ) | $ | (534,632 | ) | |||
(4,828,685 | ) | |||||||
TOTAL COMMON STOCKS | ||||||||
(Proceeds $9,830,902) | (9,793,323 | ) | ||||||
TOTAL SECURITIES SOLD SHORT | ||||||||
(Proceeds $9,830,902) | $ | (9,793,323 | ) |
Annual Report | October 31, 2020 | 19 |
Clough Global Dividend and Income Fund | Statement of Investments |
October 31, 2020
Investment Abbreviations:
1D FEDEF - Federal Funds Effective Rate (Daily)
SOFR - Secured Overnight Financing Rate
FEDEF Rates:
1D FEDEF - 1 Day FEDEF as of October 31, 2020 was 0.09%
SOFR Rates:
1D SOFR as of October 31, 2020 was 0.09%
(a) | Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of October 31, 2020, the aggregate value of those securities was $89,389,815, representing 103.92% of net assets. (See Note 1) |
(b) | Loaned security; a portion or all of the security is on loan as of October 31, 2020. |
(c) | Non-income producing security. |
(d) | This security has no contractual maturity date, is not redeemable and contractually pays an indefinite stream of interest. |
(e) | Security is exempt from registration of the Securities Act of 1933. These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of October 31, 2020, these securities had an aggregate value of $3,368,608 or 3.92% of net assets. |
(f) | Securities were purchased pursuant to Regulation S under the Securities Act of 1933, which exempts securities offered and sold outside of the United States from registration. Such securities cannot be sold in the United States without either an effective registration statement filed pursuant to the Securities Act of 1933, or pursuant to an exemption from registration. These securities have been deemed liquid under guidelines approved by the Fund's Board of Trustees. As of October 31, 2020, the aggregate value of those securities was $1,526,146, representing 1.77% of net assets. |
(g) | Variable rate investment. Interest rates reset periodically. Interest rate shown reflects the rate in effect at October 31, 2020. For securities based on a published reference rate and spread, the reference rate and spread are indicated in the description above. |
(h) | Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short. |
For Fund compliance purposes, the Fund’s sector classifications refer to any one of the sector sub-classifications used by one or more widely recognized market indexes, and/or as defined by Fund management. This definition may not apply for purposes of this report, which may combine sector sub-classifications for reporting ease. Sectors are shown as a percent of net assets. These sector classifications are unaudited.
20 | www.cloughglobal.com |
Clough Global Dividend and Income Fund | Statement of Investments |
October 31, 2020
FUTURES CONTRACTS
Description | Counterparty | Position | Contracts |
Expiration Date |
Notional Value |
Unrealized Appreciation/ (Depreciation) |
||||||||||
EURODOLLAR 90 DAY | Morgan Stanley | Long | 1,447 | June 2021 | $ | 361,026,500 | $ | 2,453,752 | ||||||||
EURODOLLAR 90 DAY | Morgan Stanley | Long | 369 | March 2022 | 91,996,312 | (116,920 | ) | |||||||||
$ | 453,022,812 | $ | 2,336,832 |
TOTAL RETURN SWAP CONTRACTS
Counter Party |
Reference Entity/Obligation |
Notional Amount |
Floating Rate Paid by the Fund |
Floating Rate Index |
Termination Date |
Value |
Net Unrealized Appreciation |
|||||||||||||
Morgan Stanley | Banco Santander SA | $ | (89,724 | ) | 1D FEDEF - 50 bps | 1D FEDEF | 05/20/2022 | $ | (85,093 | ) | $ | 4,631 | ||||||||
Morgan Stanley | Kweichow Moutai Co., Ltd. | 588,373 | 1D FEDEF - 250 bps | 1D FEDEF | 01/06/2022 | 770,180 | 181,807 | |||||||||||||
Morgan Stanley | Sany Heavy Industry Co., Ltd. | 2,161,971 | 1D FEDEF - 250 bps | 1D FEDEF | 01/06/2022 | 2,955,501 | 793,530 | |||||||||||||
Morgan Stanley | Wuliangye Yibin Co., Ltd. | 423,129 | 1D FEDEF - 255 bps | 1D FEDEF | 05/04/2022 | 795,026 | 371,897 | |||||||||||||
$ | 3,083,749 | $ | 4,435,614 | $ | 1,351,865 |
Counter Party |
Reference Entity/Obligation |
Notional Amount |
Floating Rate Paid by the Fund |
Floating Rate Index |
Termination Date |
Value |
Net Unrealized Depreciation |
|||||||||||||
Morgan Stanley | Luxshare Precision Industry Co., Ltd. | $ | 746,462 | 1D FEDEF - 250 bps | 1D FEDEF | 01/06/2022 | $ | 741,815 | $ | (4,647 | ) | |||||||||
$ | 746,462 | $ | 741,815 | $ | (4,647 | ) |
See Notes to the Financial Statements.
Annual Report | October 31, 2020 | 21 |
Clough Global Equity Fund | Statement of Investments |
October 31, 2020
Shares | Value | |||||||
COMMON STOCKS 128.67% | ||||||||
Communication Services 6.41% | ||||||||
Alphabet, Inc. - Class C(a)(b) | 2,755 | $ | 4,465,882 | |||||
Facebook, Inc. - Class A(a)(b)(c) | 15,105 | 3,974,277 | ||||||
Tencent Holdings, Ltd. | 31,750 | 2,420,413 | ||||||
10,860,572 | ||||||||
Consumer Discretionary 18.00% | ||||||||
Alibaba Group Holding, Ltd.(a) | 85,050 | 3,216,596 | ||||||
Amazon.com, Inc.(a)(b)(c) | 1,626 | 4,936,780 | ||||||
Carnival Corp.(b)(c) | 152,500 | 2,090,775 | ||||||
Carvana Co.(a)(b) | 18,950 | 3,512,383 | ||||||
DR Horton, Inc.(b)(c) | 70,900 | 4,736,829 | ||||||
Lennar Corp. - Class A(b)(c) | 63,700 | 4,473,651 | ||||||
Meituan - Class B(a) | 62,300 | 2,316,009 | ||||||
Royal Caribbean Cruises Ltd.(b)(c) | 68,720 | 3,877,182 | ||||||
Samsonite International S.A.(a) | 1,356,000 | 1,364,308 | ||||||
30,524,513 | ||||||||
Financials 30.16% | ||||||||
AGNC Investment Corp.(b) | 420,100 | 5,868,797 | ||||||
Annaly Capital Management, Inc.(b) | 832,800 | 5,904,552 | ||||||
Ares Capital Corp.(b) | 57,400 | 793,842 | ||||||
Bank of America Corp.(b)(c) | 178,095 | 4,220,852 | ||||||
Barings BDC, Inc. | 120,846 | 907,554 | ||||||
Citigroup, Inc.(b)(c) | 65,962 | 2,732,146 | ||||||
First American Financial Corp.(b)(c) | 149,700 | 6,675,123 | ||||||
Golub Capital BDC, Inc.(b) | 152,461 | 1,937,779 | ||||||
Hong Kong Exchanges and Clearing, Ltd. | 66,900 | 3,194,631 | ||||||
JPMorgan Chase & Co.(b)(c) | 28,250 | 2,769,630 | ||||||
PennyMac Financial Services, Inc.(b) | 233,400 | 11,861,387 | ||||||
Sixth Street Specialty Lending, Inc.(b)(c) | 170,000 | 2,798,200 | ||||||
Stewart Information Services Corp.(b) | 34,600 | 1,466,694 | ||||||
51,131,187 | ||||||||
Health Care 46.89% | ||||||||
1Life Healthcare, Inc.(a)(b)(c) | 119,600 | 3,373,916 | ||||||
AbbVie, Inc.(b) | 24,000 | 2,042,400 | ||||||
Amgen, Inc.(b)(c) | 14,754 | 3,200,733 | ||||||
Amphivena Therapeutics, Inc. - Series C(a)(d)(e)(f)(g) | 334,425 | 1,308,431 | ||||||
Apellis Pharmaceuticals, Inc.(a)(b)(c) | 77,397 | 2,468,964 | ||||||
Arcellx, Inc.(a)(d)(e)(f)(g) | 234,345 | 420,485 | ||||||
Baxter International, Inc.(b)(c) | 21,000 | 1,628,970 | ||||||
Centrexion Therapeutics Corp.(a)(e)(f)(g) | 4,336 | 51,741 | ||||||
Centrexion Therapeutics Corp.(a)(d)(e)(f)(g) | 66,719 | 796,158 | ||||||
Checkmate Pharmaceuticals, Inc.(a)(b)(c) | 157,641 | 1,811,295 |
Shares | Value | |||||||
Health Care (continued) | ||||||||
Checkmate Pharmaceuticals, Inc.(a)(d)(e)(g) | 112,731 | $ | 1,261,098 | |||||
Covetrus, Inc.(a)(b) | 114,100 | 2,817,129 | ||||||
CRISPR Therapeutics AG(a)(b) | 46,080 | 4,231,066 | ||||||
Flexion Therapeutics, Inc.(a)(b)(c) | 266,500 | 3,195,335 | ||||||
Fusion Pharmaceuticals, Inc.(a) | 78,000 | 967,200 | ||||||
Gossamer Bio, Inc.(a)(b) | 87,821 | 728,914 | ||||||
GW Pharmaceuticals PLC - ADR(a)(b)(c) | 31,958 | 2,876,540 | ||||||
Hologic, Inc.(a)(b)(c) | 80,000 | 5,505,600 | ||||||
Idorsia, Ltd.(a) | 21,806 | 571,696 | ||||||
Laboratory Corp. of America Holdings(a)(b)(c) | 18,410 | 3,677,766 | ||||||
McKesson Corp.(b) | 17,100 | 2,522,079 | ||||||
Mirati Therapeutics, Inc.(a)(b) | 6,570 | 1,426,610 | ||||||
Moderna, Inc.(a)(b)(c) | 58,322 | 3,934,985 | ||||||
Quest Diagnostics, Inc.(b)(c) | 50,940 | 6,221,812 | ||||||
Regeneron Pharmaceuticals, Inc.(a)(b)(c) | 3,920 | 2,130,755 | ||||||
Repare Therapeutics, Inc.(a)(b) | 56,200 | 1,519,086 | ||||||
SmileDirectClub, Inc.(a)(b) | 158,400 | 1,409,760 | ||||||
Teladoc Health, Inc.(a)(b)(c) | 14,529 | 2,854,367 | ||||||
Thermo Fisher Scientific, Inc.(b) | 8,934 | 4,226,854 | ||||||
Veracyte, Inc.(a)(b) | 74,710 | 2,589,449 | ||||||
Vertex Pharmaceuticals, Inc.(a)(b)(c) | 16,045 | 3,343,136 | ||||||
Vir Biotechnology, Inc.(a)(b) | 12,790 | 402,118 | ||||||
Zai Lab, Ltd. - ADR(a)(b)(c) | 35,290 | 2,895,544 | ||||||
Zoetis, Inc.(b)(c) | 6,855 | 1,086,860 | ||||||
79,498,852 | ||||||||
Information Technology 24.60% | ||||||||
Advanced Energy Industries, Inc.(a)(b) | 29,400 | 1,983,618 | ||||||
Apple, Inc.(b)(c) | 55,040 | 5,991,654 | ||||||
Crowdstrike Holdings, Inc. - Class A(a)(b) | 11,040 | 1,367,194 | ||||||
Five9, Inc.(a)(b) | 11,670 | 1,770,572 | ||||||
Infineon Technologies AG | 46,376 | 1,290,878 | ||||||
Intuit, Inc.(b) | 4,650 | 1,463,262 | ||||||
Lam Research Corp.(b)(c) | 6,155 | 2,105,502 | ||||||
Lumentum Holdings, Inc.(a)(b) | 19,400 | 1,604,186 | ||||||
Mastercard, Inc. - Class A(b) | 4,390 | 1,267,130 | ||||||
Microsoft Corp.(b) | 22,229 | 4,500,706 | ||||||
Qorvo, Inc.(a) | 17,540 | 2,233,894 | ||||||
Renesas Electronics Corp.(a) | 178,800 | 1,470,431 | ||||||
RingCentral, Inc. - Class A(a)(b) | 5,105 | 1,318,826 | ||||||
salesforce.com, Inc.(a)(b)(c) | 4,089 | 949,752 | ||||||
Skyworks Solutions, Inc.(b) | 10,830 | 1,530,171 | ||||||
Splunk, Inc.(a)(b) | 7,010 | 1,388,260 | ||||||
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(b)(c) | 54,500 | 4,570,915 | ||||||
Taiwan Semiconductor Manufacturing Co., Ltd. | 111,000 | 1,676,438 | ||||||
Twilio, Inc. - Class A(a)(b) | 5,600 | 1,562,232 |
22 | www.cloughglobal.com |
Clough Global Equity Fund | Statement of Investments |
October 31, 2020
Shares | Value | |||||||
Information Technology (continued) | ||||||||
Workday, Inc. - Class A(a)(b)(c) | 7,905 | $ | 1,660,999 | |||||
41,706,620 | ||||||||
Real Estate 2.61% | ||||||||
Community Healthcare Trust, Inc.(b) | 64,650 | 2,993,295 | ||||||
Physicians Realty Trust(b) | 84,600 | 1,426,356 | ||||||
4,419,651 | ||||||||
TOTAL COMMON STOCKS | ||||||||
(Cost $198,770,629) | 218,141,395 |
Underlying Security/Expiration Date/ Exercise Price/Notional Amount |
Contracts | Value | ||||||
PURCHASED OPTIONS 1.33% | ||||||||
Call Options Purchased 1.33% | ||||||||
CRISPR Therapeutics AG | ||||||||
01/15/21, $90, $4,131,900 | 450 | 695,250 | ||||||
Eurodollar Future Option | ||||||||
12/14/21, $100, $654,307,350 | 2,623 | 180,332 | ||||||
12/14/21, $99.875, $997,800,000 | 4,000 | 375,000 | ||||||
Hologic, Inc. | ||||||||
12/18/20, $70, $8,086,350 | 1,175 | 511,125 | ||||||
Vertex Pharmaceuticals, Inc. | ||||||||
01/15/21, $210, $7,084,240 | 340 | 498,100 | ||||||
Total Call Options Purchased | ||||||||
(Cost $3,415,259) | 2,259,807 |
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
GOVERNMENT & AGENCY OBLIGATIONS 15.15% | ||||||||
U.S. Treasury Bonds | ||||||||
02/15/2050, 2.000%(b) | $ | 6,800,000 | 7,363,125 | |||||
05/15/2050, 1.250% | 2,700,000 | 2,438,437 | ||||||
08/15/2050, 1.375% | 8,000,000 | 7,458,750 | ||||||
U.S. Treasury Notes | ||||||||
02/28/2027, 1.125% | 2,000,000 | 2,069,180 | ||||||
02/15/2030, 1.500%(b) | 6,000,000 | 6,360,000 | ||||||
TOTAL GOVERNMENT & AGENCY OBLIGATIONS | ||||||||
(Cost $26,843,161) | 25,689,492 |
Shares | Value | |||||||
SHORT-TERM INVESTMENTS 1.95% | ||||||||
Money Market Funds 1.95% | ||||||||
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.040% 7-day yield) | 3,307,238 | 3,307,238 | ||||||
TOTAL SHORT-TERM INVESTMENTS | ||||||||
(Cost $3,307,238) | 3,307,238 |
Value | ||||
Total Investments - 147.10% | ||||
(Cost $232,336,287) | $ | 249,397,932 | ||
Liabilities in Excess of Other Assets - (47.10%)(h) | (79,856,007 | ) | ||
NET ASSETS - 100.00% | $ | 169,541,925 |
Investment Abbreviations:
1D FEDEF - Federal Funds Effective Rate (Daily)
FEDEF Rates:
1D FEDEF - 1 Day FEDEF as of October 31, 2020 was 0.09%
Annual Report | October 31, 2020 | 23 |
Clough Global Equity Fund | Statement of Investments |
October 31, 2020
(a) | Non-income producing security. |
(b) | Pledged security; a portion or all of the security is pledged as collateral for securities sold short, total return swap contracts, or borrowings. As of October 31, 2020, the aggregate value of those securities was $186,535,925, representing 110.02% of net assets. (See Note 1) |
(c) | Loaned security; a portion or all of the security is on loan as of October 31, 2020. |
(d) | All or a portion of the security is exempt from registration of the Securities Act of 1933. These securities may be resold in transactions exempt from registration under Rule 144A, normally to qualified institutional buyers. As of October 31, 2020, these securities had an aggregate value of $3,786,172 or 2.23% of net assets. |
(e) | Private Placement; these securities may only be resold in transactions exempt from registration under the Securities Act of 1933. As of October 31, 2020, these securities had an aggregate value of $3,837,913 or 2.26% of net assets. |
(f) | As a result of the use of significant unobservable inputs to determine fair value, these investments have been classified as Level 3 assets. (See Note 1) |
(g) | Fair valued security; valued by management in accordance with procedures approved by the Board. As of October 31, 2020, these securities had an aggregate value of $3,837,913 or 2.26% of total net assets. |
(h) | Includes cash which is being held as collateral for futures contracts, total return swap contracts and securities sold short. |
For Fund compliance purposes, the Fund’s sector classifications refer to any one of the sector sub-classifications used by one or more widely recognized market indexes, and/or as defined by Fund management. This definition may not apply for purposes of this report, which may combine sector sub-classifications for reporting ease. Sectors are shown as a percent of net assets. These sector classifications are unaudited.
24 | www.cloughglobal.com |
Clough Global Equity Fund | Statement of Investments |
October 31, 2020
FUTURES CONTRACTS
Description |
Counterparty | Position | Contracts |
Expiration Date |
Notional Value |
Unrealized Appreciation/ (Depreciation) |
||||||||||
EURODOLLAR 90 DAY | Morgan Stanley | Long | 2,467 | June 2021 | $ | 615,516,500 | $ | 4,341,400 | ||||||||
EURODOLLAR 90 DAY | Morgan Stanley | Long | 695 | March 2022 | 173,272,188 | (220,214 | ) | |||||||||
$ | 788,788,688 | $ | 4,121,186 |
TOTAL RETURN SWAP CONTRACTS
Counter Party |
Reference Entity/Obligation |
Notional Amount |
Floating Rate Paid by the Fund |
Floating Rate Index |
Termination Date |
Value |
Net Unrealized Appreciation |
||||||||||||
Morgan Stanley | Banco Santander SA | $ | (153,443 | ) | 1D FEDEF -50 bps | 1D FEDEF | 05/20/2022 | $ | (145,523 | ) | $ | 7,920 | |||||||
Morgan Stanley | Kweichow Moutai Co., Ltd. | 1,155,801 | 1D FEDEF -250 bps | 1D FEDEF | 01/06/2022 | 1,512,943 | 357,142 | ||||||||||||
Morgan Stanley | Luxshare Precision Industry Co., Ltd. | 2,126,874 | 1D FEDEF - 250 bps | 1D FEDEF | 01/06/2022 | 2,591,584 | 464,710 | ||||||||||||
Morgan Stanley | Sany Heavy Industry Co., Ltd. | 3,476,687 | 1D FEDEF -250 bps | 1D FEDEF | 01/06/2022 | 4,811,838 | 1,335,151 | ||||||||||||
Morgan Stanley | Wuliangye Yibin Co., Ltd. | 830,731 | 1D FEDEF -255 bps | 1D FEDEF | 05/04/2022 | 1,560,876 | 730,145 | ||||||||||||
Morgan Stanley | Zoomlion Heavy Industry Science | 2,204,767 | 1D FEDEF - 250 bps | 1D FEDEF | 01/06/2022 | 2,376,765 | 171,998 | ||||||||||||
TOTAL | $ | 9,641,417 | $ | 12,708,483 | $ | 3,067,066 |
See Notes to the Financial Statements.
Annual Report | October 31, 2020 | 25 |
Clough Global Opportunities Fund | Statement of Investments |
October 31, 2020
Shares | Value | |||||||
COMMON STOCKS 120.87% | ||||||||
Communication Services 6.42% | ||||||||
Alphabet, Inc. - Class C(a)(b) | 5,469 | $ | 8,865,304 | |||||
Facebook, Inc. - Class A(a)(b)(c) | 30,335 | 7,981,442 | ||||||
Tencent Holdings, Ltd. | 63,500 | 4,840,825 | ||||||
21,687,571 | ||||||||
Consumer Discretionary 16.05% | ||||||||
Alibaba Group Holding, Ltd.(a) | 171,620 | 6,490,678 | ||||||
Amazon.com, Inc.(a)(b) | 1,670 | 5,070,371 | ||||||
Carnival Corp.(b)(c) | 303,840 | 4,165,646 | ||||||
Carvana Co.(a)(b) | 38,208 | 7,081,853 | ||||||
DR Horton, Inc.(b)(c) | 125,800 | 8,404,698 | ||||||
Lennar Corp. - Class A(b)(c) | 112,200 | 7,879,806 | ||||||
Meituan - Class B(a) | 123,400 | 4,587,408 | ||||||
Royal Caribbean Cruises Ltd.(b)(c) | 138,347 | 7,805,538 | ||||||
Samsonite International S.A.(a) | 2,718,600 | 2,735,257 | ||||||
54,221,255 | ||||||||
Financials 27.72% | ||||||||
AGNC Investment Corp.(b) | 729,100 | 10,185,527 | ||||||
Annaly Capital Management, Inc.(b) | 1,660,100 | 11,770,109 | ||||||
Ares Capital Corp.(b) | 114,583 | 1,584,683 | ||||||
Bank of America Corp.(b) | 319,430 | 7,570,491 | ||||||
Barings BDC, Inc.(b) | 244,400 | 1,835,444 | ||||||
Citigroup, Inc.(b)(c) | 131,141 | 5,431,860 | ||||||
First American Financial Corp.(b)(c) | 270,565 | 12,064,493 | ||||||
Golub Capital BDC, Inc.(b) | 171,896 | 2,184,798 | ||||||
Hong Kong Exchanges and Clearing, Ltd. | 134,300 | 6,413,139 | ||||||
JPMorgan Chase & Co.(b)(c) | 49,800 | 4,882,392 | ||||||
PennyMac Financial Services, Inc.(b) | 462,080 | 23,482,905 | ||||||
Sixth Street Specialty Lending, Inc.(b)(c) | 198,627 | 3,269,400 | ||||||
Stewart Information Services Corp.(b)(c) | 69,400 | 2,941,866 | ||||||
93,617,107 | ||||||||
Health Care 45.90% | ||||||||
1Life Healthcare, Inc.(a)(b)(c) | 239,600 | 6,759,116 | ||||||
AbbVie, Inc.(b) | 47,800 | 4,067,780 | ||||||
Amgen, Inc.(b)(c) | 29,570 | 6,414,916 | ||||||
Amphivena Therapeutics, Inc. - Series C(a)(d)(e)(f)(g) | 780,326 | 3,053,009 | ||||||
Apellis Pharmaceuticals, Inc.(a)(b)(c) | 156,301 | 4,986,002 | ||||||
Arcellx, Inc.(a)(d)(e)(f)(g) | 538,792 | 966,754 | ||||||
Baxter International, Inc.(b) | 42,100 | 3,265,697 | ||||||
Centrexion Therapeutics Corp.(a)(e)(f)(g) | 14,166 | 169,043 | ||||||
Centrexion Therapeutics Corp.(a)(d)(e)(f)(g) | 217,952 | 2,600,821 |
Shares | Value | |||||||
Health Care (continued) | ||||||||
Checkmate Pharmaceuticals, Inc.(a)(d)(e)(g) | 225,463 | $ | 2,522,208 | |||||
Checkmate Pharmaceuticals, Inc.(a)(b)(c) | 320,465 | 3,682,143 | ||||||
Covetrus, Inc.(a)(b) | 226,800 | 5,599,692 | ||||||
CRISPR Therapeutics AG(a)(b) | 107,438 | 9,864,957 | ||||||
Flexion Therapeutics, Inc.(a)(b)(c) | 528,450 | 6,336,115 | ||||||
Fusion Pharmaceuticals, Inc.(a) | 156,700 | 1,943,080 | ||||||
Gossamer Bio, Inc.(a)(b) | 180,188 | 1,495,560 | ||||||
GW Pharmaceuticals PLC - ADR(a)(b)(c) | 64,064 | 5,766,401 | ||||||
Hologic, Inc.(a)(b)(c) | 159,300 | 10,963,026 | ||||||
Laboratory Corp. of America Holdings(a)(b)(c) | 36,895 | 7,370,514 | ||||||
McKesson Corp.(b)(c) | 34,020 | 5,017,610 | ||||||
Mirati Therapeutics, Inc.(a)(b) | 13,185 | 2,862,991 | ||||||
Moderna, Inc.(a)(b)(c) | 116,110 | 7,833,942 | ||||||
Quest Diagnostics, Inc.(b)(c) | 102,090 | 12,469,273 | ||||||
Regeneron Pharmaceuticals, Inc.(a)(b)(c) | 7,878 | 4,282,166 | ||||||
Repare Therapeutics, Inc.(a) | 111,679 | 3,018,683 | ||||||
SmileDirectClub, Inc.(a)(b) | 317,100 | 2,822,190 | ||||||
Teladoc Health, Inc.(a)(b)(c) | 29,541 | 5,803,625 | ||||||
Thermo Fisher Scientific, Inc.(b)(c) | 17,907 | 8,472,160 | ||||||
Vertex Pharmaceuticals, Inc.(a)(b)(c) | 32,153 | 6,699,399 | ||||||
Vir Biotechnology, Inc.(a) | 25,583 | 804,329 | ||||||
Zai Lab, Ltd. - ADR(a)(b)(c) | 71,220 | 5,843,601 | ||||||
Zoetis, Inc.(b)(c) | 8,005 | 1,269,193 | ||||||
155,025,996 | ||||||||
Information Technology 22.36% | ||||||||
Advanced Energy Industries, Inc.(a) | 58,800 | 3,967,236 | ||||||
Apple, Inc.(b) | 109,610 | 11,932,145 | ||||||
Crowdstrike Holdings, Inc. - Class A(a)(b)(c) | 21,960 | 2,719,526 | ||||||
Five9, Inc.(a)(b)(c) | 23,350 | 3,542,662 | ||||||
Infineon Technologies AG | 92,045 | 2,562,076 | ||||||
Intuit, Inc.(b)(c) | 9,310 | 2,929,671 | ||||||
Lam Research Corp.(b)(c) | 7,660 | 2,620,333 | ||||||
Lumentum Holdings, Inc.(a) | 38,600 | 3,191,834 | ||||||
Mastercard, Inc. - Class A(b) | 8,717 | 2,516,075 | ||||||
Microsoft Corp.(b)(c) | 39,503 | 7,998,172 | ||||||
Qorvo, Inc.(a)(b)(c) | 35,270 | 4,491,987 | ||||||
Renesas Electronics Corp.(a) | 354,400 | 2,914,546 | ||||||
RingCentral, Inc. - Class A(a)(b)(c) | 10,220 | 2,640,235 | ||||||
Skyworks Solutions, Inc. | 21,610 | 3,053,277 | ||||||
Splunk, Inc.(a) | 14,060 | 2,784,442 | ||||||
Taiwan Semiconductor Manufacturing Co., Ltd. - Sponsored ADR(b)(c) | 108,800 | 9,125,056 | ||||||
Taiwan Semiconductor Manufacturing Co., Ltd. | 225,000 | 3,398,186 |
26 | www.cloughglobal.com |
Clough Global Opportunities Fund | Statement of Investments |
October 31, 2020
Shares | Value | |||||||
Information Technology (continued) | ||||||||
Twilio, Inc. - Class A(a)(b)(c) | 11,200 | $ | 3,124,464 | |||||
75,511,923 | ||||||||
Real Estate 2.42% | ||||||||
Community Healthcare Trust, Inc.(b) | 113,356 | 5,248,383 | ||||||
Physicians Realty Trust(b) | 174,000 | 2,933,640 | ||||||
8,182,023 | ||||||||
TOTAL COMMON STOCKS | ||||||||
(Cost $373,011,039) | 408,245,875 | |||||||
Underlying Security/Expiration Date/Exercise Price/Notional Amount | Contracts | Value | ||||||
PURCHASED OPTIONS 1.33% | ||||||||
Call Options Purchased 1.33% | ||||||||
CRISPR Therapeutics AG | ||||||||
01/15/21, $90, $8,263,800 | 900 | 1,390,500 | ||||||
Eurodollar Future Option | ||||||||
12/14/21, $100, $1,322,833,350 | 5,303 | 364,581 | ||||||
12/14/21, $99.875, $1,970,655,000 | 7,900 | 740,625 | ||||||
Hologic, Inc. | ||||||||
12/18/20, $70, $16,172,700 | 2,350 | 1,022,250 | ||||||
Vertex Pharmaceuticals, Inc. | ||||||||
01/15/21, $210, $13,960,120 | 670 | 981,550 | ||||||
Total Call Options Purchased | ||||||||
(Cost $6,799,089) | 4,499,506 | |||||||
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
CORPORATE BONDS 3.30% | ||||||||
Agile Group Holdings, Ltd. | ||||||||
11/23/2020, 9.500%(h) | $ | 750,000 | 752,293 | |||||
Duke University | ||||||||
Series 2020, 10/01/2044, 2.682% | 1,500,000 | 1,532,203 | ||||||
Fidelity National Financial, Inc. | ||||||||
03/15/2031, 2.450% | 1,400,000 | 1,371,725 | ||||||
Regeneron Pharmaceuticals, Inc. | ||||||||
09/15/2050, 2.800% | 1,300,000 | 1,220,638 | ||||||
Stanford Health Care | ||||||||
Series 2020, 08/15/2030, 3.310% | 1,300,000 | 1,456,558 | ||||||
Sunac China Holdings, Ltd. | ||||||||
04/19/2023, 8.350%(h) | 2,250,000 | 2,310,284 | ||||||
Times China Holdings, Ltd. | ||||||||
06/04/2021, 7.850%(h) | 1,500,000 | 1,515,860 | ||||||
University of Notre Dame du Lac | ||||||||
Series 2020, 02/15/2030, 1.637% | 1,000,000 | 1,005,760 | ||||||
TOTAL CORPORATE BONDS | ||||||||
(Cost $11,389,332) | 11,165,321 |
Description/Maturity Date/Rate |
Principal Amount |
Value | ||||||
CONVERTIBLE CORPORATE BONDS 0.15% | ||||||||
Two Harbors Investment Corp. | ||||||||
01/15/2022, 6.250% | $ | 500,000 | $ | 499,688 | ||||
TOTAL CONVERTIBLE CORPORATE BONDS | ||||||||
(Cost $498,986) | 499,688 | |||||||
GOVERNMENT & AGENCY OBLIGATIONS 17.88% | ||||||||
U.S. Treasury Bonds | ||||||||
11/15/2042, 2.750%(b) | 8,420,000 | 10,434,551 | ||||||
02/15/2050, 2.000%(b) | 8,500,000 | 9,203,906 | ||||||
05/15/2050, 1.250% | 3,100,000 | 2,799,687 | ||||||
08/15/2050, 1.375% | 12,000,000 | 11,188,125 | ||||||
U.S. Treasury Notes | ||||||||
02/28/2025, 1.125%(b) | 9,000,000 | 9,313,594 | ||||||
03/31/2025, 2.625% | 5,000,000 | 5,502,344 | ||||||
02/28/2027, 1.125%(b) | 5,400,000 | 5,586,785 | ||||||
02/15/2030, 1.500%(b) | 6,000,000 | 6,360,000 | ||||||
TOTAL GOVERNMENT & AGENCY OBLIGATIONS | ||||||||
(Cost $62,439,186) | 60,388,992 | |||||||
MUNICIPAL BONDS 0.70% | ||||||||
University of Virginia, Higher Education Revenue Bonds | ||||||||
09/01/2050, 2.256% | 2,500,000 | 2,353,050 | ||||||
TOTAL MUNICIPAL BONDS | ||||||||
(Cost $2,531,041) | 2,353,050 | |||||||
Shares | Value | |||||||
SHORT-TERM INVESTMENTS 2.86% | ||||||||
Money Market Funds 2.86% | ||||||||
BlackRock Liquidity Funds, T-Fund Portfolio - Institutional Class (0.040% 7-day yield) | 9,658,221 | 9,658,221 | ||||||
TOTAL SHORT-TERM INVESTMENTS | ||||||||
(Cost $9,658,221) | 9,658,221 | |||||||
Total Investments - 147.09% | ||||||||
(Cost $466,326,894) | 496,810,653 | |||||||
Liabilities in Excess of Other Assets - (47.09%)(i) | (159,049,392 | ) | ||||||
NET ASSETS - 100.00% | $ | 337,761,261 | ||||||
SCHEDULE OF SECURITIES SOLD SHORT(a) |
Shares | Value | ||||||
COMMON STOCKS (10.75%) | ||||||||
Consumer Discretionary (0.63%) | ||||||||
Vroom, Inc. | (51,800 | ) | (2,128,980 | ) |
Annual Report | October 31, 2020 | 27 |
Clough Global Opportunities Fund | Statement of Investments |
October 31, 2020